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ABSTRACT OF DISSERTATION 
 
 
 
 
CYCLOOXYGENASE-2-DEPENDENT REMODELING OF 
THE DUCTUS ARTERIOSUS 
 
Transition of the cardiopulmonary circulation at birth requires functional closure 
of the ductus arteriosus (DA). The DA is an arterial shunt that is vital in the fetus for 
diverting the pulmonary circulation away from the uninflated lungs. Failure of the vessel 
to functionally close after birth is known as patent DA, which is the second most 
common congenital heart disease. Patent DA may seriously compromise neonatal health 
and current pharmacological treatments are often limited by serious complications or a 
significant failure rate, thereby increasing the necessity for surgical intervention. 
Recently, we were the first to show that genetic or pharmacological inactivation of 
cyclooxygenase (COX) -2 produces postnatal patent DA in mice. We also demonstrated 
that the DA expresses high levels of COX-2 during normal closure after birth, suggesting 
novel contractile actions of COX-2-dependent prostanoids in the DA. In humans, patent 
DA is more common in preterm infants than those born at full-term, however, 
mechanism(s) responsible for the reduced DA closure have not been identified.  
In the current studies, we examined COX-1 and COX-2 expression in the DA at 
multiple stages of gestation to determine whether alterations in the expression of these 
enzymes contribute to patent DA in preterm mice. Using real-time PCR, analysis of the 
time-course of COX-2 mRNA in the fetal mouse DA indicated that COX-2 expression 
significantly increased with advancing gestational age. The preterm (day 17.5) neonatal 
mouse DA showed attenuated COX-2 expression, as compared to the full-term (day 19.5) 
neonatal DA at 3 hours after birth. Furthermore, the DA of preterm neonatal mice showed 
incomplete closure after 3 hours of birth, a time-point when the DA of full-term neonates 
was completely remodeled. These data indicate a correlation between reduced DA 
closure and attenuated COX-2 expression. 
Additionally, COX-2 expression was significantly attenuated in the DA of mice 
deficient in the prostanoid receptor EP4, which also show a patent DA phenotype, 
suggesting the importance of this receptor for the induction of COX-2 required for DA 
closure. Overall, these studies suggest that attenuated expression of COX-2 may 
contribute to increased patent DA at preterm gestation.  
 
KEYWORDS: cyclooxygenase-2, ductus arteriosus, prostanoid receptors, congenital 
heart defects, vascular remodeling 
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CHAPTER 1 
BACKGROUND 
 
THE DUCTUS ARTERIOSUS 
The ductus arteriosus (DA) is a muscular artery in the fetus which connects the 
main pulmonary artery and the descending aorta and functions in utero to divert greater 
than 90% of the right ventricular cardiac output to bypass the uninflated lungs.
1
 Loss of 
the maternal oxygen supply at birth necessitates rapid initiation of pulmonary function 
and transition of the cardiopulmonary circulation in the newborn. An essential component 
of this postnatal circulatory remodeling is the functional closure of the DA. In the healthy 
full-term infant, DA constriction begins after birth to initiate functional closure during the 
first few days of life.
2
 
 
Developmental Origin of the DA  
During embryonic development, the DA originates together with other great 
arteries, from the pharyngeal arterial system. Even though the cells forming the heart and 
circulatory system are of mesodermal origin, the arches of the pharyngeal arterial system 
are populated with cardiac neural crest cells, which also contribute to formation of the 
vessel wall. Studies in the chick and mammalian embryos have shown that cardiac neural 
crest derived cells contribute to a variety of cells in the arches, including the arterial 
smooth muscle cells (SMCs).
3
 Even though anatomical diversity exists in the aortic arch 
system in all vertebrates, the ancestral arterial system from which it is derived consists of 
6 aortic arches. It is known that lung-bearing vertebrates including lungfish, amphibians, 
reptiles, birds, marsupials and mammals, all possess a DA. Despite the diversity in the 
remodeling of the arterial system, the DA in all air-breathing vertebrates develops from a 
specific segment of the sixth arch of the pharyngeal arterial system. Throughout 
development, the DA undergoes a unique differentiation program, which prepares it for 
closure in the newborn at the stage involving lung respiration. This in utero 
differentiation of the DA occurs during the final one-third of gestation with full 
contractile ability occurring only at full-term. Particularly, in all mammals, when the 
transition to pulmonary respiration occurs, the DA rapidly closes after birth.
4
 
 2 
 
Anatomic Closure of the DA. 
DA closure after birth occurs in two phases. The first phase involves constriction 
of smooth muscle, which obstructs the DA lumen. The second phase involves anatomical 
remodeling of the vessel, which results in permanent closure. In humans, permanent 
closure of the DA is complete within a few days of birth, whereas in mice, complete 
closure is achieved within 3 hours of birth. Permanent remodeling of the DA involves 
extensive intimal thickening and intimal cushion formation, which begins with the lifting, 
infolding and in-growth of the endothelial cells, followed by migration of SMC from the 
media, into the subendothelial space.
2, 4
 Increased production of specific extracellular 
matrix components such as hyaluronic acid, chondroitin sulfate and fibronectin is also 
associated with intimal cushion formation. DA remodeling also involves disassembly of 
the internal elastic lamina and loss of elastin to promote SMC migration.
5
 
Release of extracellular matrix is also an important component of DA remodeling. 
The DA smooth muscle is involved in complex interactions with molecules of the 
extracellular matrix such as laminin, fibronectin, growth factors (e.g. TGF-!), endothelial 
hyaluronic acid and chondrotin sulfate.
2
 Studies by Mason et al. demonstrated that 
inhibition of fibronectin production inhibited DA remodeling, emphasizing the 
importance of fibronectin in the intimal cushion formation during DA remodeling.
6
 The 
interaction of the DA smooth muscle to the components of the extracellular matrix is 
facilitated by the action of specific cell surface receptors. The integrin family of receptors 
is thought to play an important role in the remodeling of the endothelial and SMCs of the 
DA. Specifically, several studies in vitro have suggested a role for several members of 
the integrin family of receptors including, "v!1 and "v!3, in the attachment and 
migration of SMCs to the extracellular matrix, to produce obliteration of the DA lumen.
7
 
DA remodeling is also thought to require a significant degree of hypoxia of DA 
smooth muscle. Studies by Clyman et al. have demonstrated a significant contribution of 
vascular endothelial growth factor (VEGF) in producing neointimal expansion during 
hypoxia-induced remodeling of the DA.
8
 It was suggested that VEGF-induced cell 
migration in the DA may be mediated by the "v!3 integrin which is upregulated during 
DA closure.
7, 9
 In addition to the migration of SMCs, inflammatory cell infiltration into 
 3 
the vessel may also contribute DA remodeling during closure. A recent study by Waleh et 
al. proposed that the remodeling of the DA involves processes similar to those observed 
during pathological remodeling in diseases such as atherosclerosis.
10
 These studies 
showed that postnatal DA remodeling involves an inflammatory response in which 
monocytes/macrophages and to some extent T-lymphocytes, are recruited in the DA 
lumen. 
Following remodeling of DA SMC, significant apoptosis and cytolytic necrosis 
are thought to be required for complete obliteration of the DA.
11, 12
 The inner intimal 
region of the DA has been shown to significantly express markers of apoptosis during 
anatomical remodeling of the DA. The SMCs in this region of the DA which are 
originally highly differentiated during initial DA constriction, then become de-
differentiated during complete DA closure and undergo cytolytic necrosis during the final 
stage of DA development.
12
 The SMCs in the inner and outer media have different 
apoptotic properties. The outer media has more prominent apoptosis in the beginning, 
which then changes into apoptosis of the inner media. It is suggested that the cytolytic 
necrosis or ischemic degeneration observed in the DA is a result of the sustained 
contraction of the SMCs and occurs following the apoptotic events. Following the 
apoptotic and necrotic events, there is a sustained and complete loss of blood supply and 
the vessel degenerates into the ligamentum arteriosum. which in the adult is only a 
remnant of the DA.  
 
Patent Ductus Arteriosus 
Infants born premature show an increased risk for developing a number of serious 
complications during the neonatal period, particularly those related to the 
cardiopulmonary circulation. One of the frequent complications of prematurity is patent 
DA, which is the second most common congenital heart disease.
13, 14
 Patent DA is the 
delay or complete failure of DA closure during the first few days after birth. The 
incidence of patent DA increases with the degree of infant prematurity and is often 
observed in combination with respiratory distress. For infants with symptoms of 
respiratory distress, patent DA occurs in one-quarter of neonates born from 30-33 weeks 
of gestation, whereas the incidence is greater than 75% in extremely premature infants 
 4 
born less than 29 weeks of gestation.
15
 Alterations in systemic or pulmonary circulation 
produce three types of cardiovascular manifestations associated with patent DA.
16, 17
 
First, because of reduced pulmonary vascular resistance following birth, patent DA 
produces a left-to-right shunting of the circulation from the aorta into the pulmonary 
arteries. Recirculation of oxygenated blood through the lungs overburdens the heart and 
predisposes the infant to congestive heart failure. Second, diversion of blood flow in the 
aorta through a patent DA produces tissue specific deficits in perfusion, which increases 
susceptibility to intraventricular hemorrhage, necrotizing enterocolitis, cerebral ischemia 
and renal insufficiency. Third, blood flow through the patent DA into the lungs 
contributes to pulmonary hypertension and edema, thereby compromising lung 
compliance and gas exchange, and increasing pneumonia susceptibility.  
 
Current Treatments for Patent DA 
Surgical ligation or indomethacin administration are the most utilized methods of 
treating patent DA in preterm neonates.
18
 Although surgical ligation may be the initial 
treatment in complicated cases when cardiothoracic teams are available, DA ligation is a 
major operation which requires thoracotomy and may have complications of its own.
17
 
Because of these limitations, intravenous administration of indomethacin is most often 
the first-line treatment for patent DA in preterm neonates. Although indomethacin 
induces an initial constriction of the DA in a majority of treated neonates, it is 
significantly less effective in achieving permanent closure, with DA reopening reported 
to occur in from 30% to greater than 50% of the treated preterm neonates.
17, 19, 20
 The use 
of indomethacin may also compromise neonatal health by reducing intestinal, cerebral 
and renal blood flow.
21-25
 Novel approaches need to be developed that are more safe and 
effective than indomethacin to reduce the necessity for surgical ligation to permanently 
close the DA in preterm infants. 
 5 
FIGURE 1.1 A. Illustration of the fetal circulation before birth.  
Arrows indicate the direction of the flow of blood from the right ventricle to the 
DA, bypassing the pulmonary arteries, thereby allowing majority of the blood to bypass 
the lungs. 
 6 
Figure 1.1 B. Illustration of patent DA
26
 
Arrows indicate the back-flow of the oxygenated blood from the aorta to the DA, 
with some of the flow directed back through the pulmonary arteries to the lungs.  
 7 
 
PROSTAGLANDINS and CYCLOOXYGENASES  
Prostaglandins (PGs) are bioactive lipid mediators derived from arachidonic acid 
(AA), that were originally extracted from the prostate, semen and seminal vesicles, early 
in the 1930s.
27
 They were first shown to cause contraction of smooth muscle and 
reduction in blood pressure. It is now known that prostaglandins are formed by most cells 
in the body and act as autocrine or paracrine lipid mediators. Prostaglandins are not 
stored but are synthesized de novo from membrane-released arachidonic acid, when cells 
are stimulated by specific cytokines, grown factors, mechanical trauma, or other stimuli. 
The release of arachidonic acid from membranes is controlled by a host of phospholipase 
A2 enzymes, and type IV cytosolic phospholipase A2 (cPLA2) shows preference for the 
release of phospholipids containing arachidonic acid. The activity of cPLA2 is tightly 
regulated by the control of translocation to the nuclear envelope, endoplasmic reticulum 
and the Golgi apparatus following agonist-dependent cell stimulation.
28-31
 
At the ER and nuclear membrane, arachidonic acid that is released by cPLA2 or 
other phospholipases, is acted upon by an enzyme known as prostaglandin H synthase 
(PGHS). The biosynthesis of prostaglandins is dependent upon PGHS, which catalyzes 
the first committed step in the pathway.
32
 The enzyme is also known as cyclooxygenase 
(COX), which was used to describe the first of two enzymatic activities of the protein, 
and is present as two isoforms, COX-1 and COX-2. The cyclooxygenase reaction 
involved in the synthesis of prostaglandins is a two-step reaction. The first step involves 
the oxygenation of arachidonic acid, which is enzymatically cyclized to yield 
endoperoxide-containing prostaglandin G2 (PGG2), by the insertion of two oxygen 
molecules. The protein also enzymatically reduces PGG2 to PGH2 via a separate 
peroxidase active site. PGH2 is then converted enzymatically or by non-enzymatic 
hydrolysis to yield the biologically active PGs, PGE2, PGF2", PGD2 and PGI2 
(prostacyclin), as well, as thromboxane A2, and collectively these are known as 
prostanoids. These biologically active prostanoids exit the cell to activate G-protein 
couple receptors to mediate their biological functions.
27, 30, 31, 33-38 
 
 
 8 
COX-1  
COX-1 is constitutively expressed and is primarily localized in the endoplasmic 
reticulum. Traditionally, it was thought that prostanoids produced by this constitutively 
expressed COX-1 were responsible for mediating physiological housekeeping functions. 
Particularly high levels of COX-1 are found in platelets, kidney, stomach and skin, 
tissues and organs in which prostanoids have particularly specialized signaling functions. 
COX-1 expression increases in cell lines that undergo differentiation, and changes in 
COX-1 expression are primarily thought to be associated with alterations in the 
developmental status of the cell. Ram seminal vesicles have long been use as a tissue for 
isolation of COX-1 protein for enzymatic studies, and in 1989 the COX-1 gene was first 
cloned from sheep, and later the complete amino acid sequence of the human COX-1 
gene was determined.
39-41
 The gene for COX-1 is approximately 22 kb in length with 11 
exons resulting in the protein consisting of 576 amino acids with a molecular mass of 
approximately 70 kDa. The 5' flanking region of the COX-1 gene does not contain a 
TATA box, which is characteristic of a housekeeping gene. There are several regulatory 
elements present in the COX-1 promoter, which include, two Sp1 motifs, two AP2 sites 
and an NF-IL6 motif.
42
 Studies with human umbilical vein endothelial cells (HUVEC), 
have shown that Sp1 cis-regulatory element, contributes to the constitutive expression of 
COX-1. It was shown that mutation of either Sp1 sites, resulted in a reduction of the 
promoter activity by 50%, as compared to the wild-type, whereas mutations in both the 
Sp1 sites, resulted in reduction of the basal activity by 75%.
27, 36, 42
 
 
COX-2 
COX-2 was discovered in the early 90s as primary response gene.
38, 43-50
 COX-2 
is an inducible enzyme, and is traditionally thought to play an important role in the 
production of prostanoids that primarily contribute to pathological conditions. The 
expression of COX-2 is known to increase in response to stimuli in various tissues and 
cells. COX-2 is primarily localized in the nuclear envelope, and various pro-
inflammatory factors such as IL-1, TNF-alpha, INF-gamma, lipopolysaccharide (LPS), 
TPA, hormones such as FSH and LH, and several growth factors including EGF, PDFG 
and FGF are known to stimulate expression of COX-2. The COX-2 gene is located on a 
 9 
separate chromosome than COX-1, which for humans is chromosome 1.
51
 The COX-2 
promoter contains the TATA box, as well as binding sites for several transcription factors 
such as NF-#B, NF-IL6, as well as the cyclic AMP response element binding protein 
(CREB).
27, 51, 52
 The 3 main MAPK pathways, including ERK1/2, JNK/SAPK and p38 
are known to contribute to the induction of the COX-2 gene.
27, 36, 42
 
 
Inhibition of COX activity 
The amino acid sequence for COX-1 and COX-2 share a 60% identity.
53
 There 
are 3 distinct domains that comprise the structure of the COX proteins: an N-terminal 
epidermal growth factor domain, a membrane binding motif, and a C-terminal catalytic 
domain that consists of the COX and peroxidase active sites. The COX active site is 
situated at the end of a hydrophobic channel that runs from the membrane-binding 
surface of the enzyme into the interior of the molecule.
54, 55
 
Non-steroidal anti-inflammatory drugs (NSAIDs), such as aspirin have been 
prominent anti-inflammatory, analgesic and antipyretic medications since 1889 when 
aspirin was first marketed. NSAIDs act on the COX active site in several ways. Aspirin 
irreversibly inactivates both COX-1 and COX-2 (primarily COX-1) by acetylating an 
active serine site at residue 530.
56
 This is a covalent modification that interferes with the 
positioning of arachidonic acid into the active site. In contrast, drugs such as ibuprofen 
are reversible competitive inhibitors of both COX isoforms, that compete with 
arachidonic acid at the COX active site.
57
 Drugs such as flurbiprofen and indomethacin 
are a third class of NSAIDs that cause a slow, time-dependent irreversible inhibition of 
COX-1 and COX-2.
31, 56, 58
 
Traditional NSAIDs such as ibuprofen and indomethacin, which inhibit the 
activity of both COX-1 and COX-2, provide significant therapeutic efficacy. However, 
the chronic use of these medications is associated with severe side effects such as 
gastrointestinal ulcerations and bleeding. Because COX-1 is not up-regulated during 
inflammatory conditions and was thought to be involved in housekeeping functions such 
as cytoprotection of the gastric mucosa, the side effects of traditional NSAIDs were 
attributed to the inhibition of COX-1. Whereas, because COX-2 was known to be up-
regulated primarily during pathological conditions such as pain and inflammation, the 
 10 
therapeutic effects of traditional NSAIDs were attributed to inhibition of COX-2. 
Because of this rationale, the identification of drugs that selectively inhibit COX-2 
activity, became the focus of NSAID development. 
The crystal structures for COX-1 and COX-2 are remarkably similar, and have 
provided insight into how specificity for COX-2 is achieved.
55, 59
 There is a single amino 
acid difference within the hydrophobic channel of the COX enzyme at position 523 
(isoleucine in COX-1 and valine in COX-2), which has been shown to be critical for the 
selectivity of several drugs for COX-2.
60
 It is thought that the smaller valine molecule in 
COX-2 creates a larger 'side-pocket' which gives substrate access to COX-2. This results 
in a 17% increase in NSAID binding by the COX-2 active site, and allows for 
development of more bulky inhibitors with COX-2 binding capability which are not 
efficiently bound by COX-1.
36
 Celecoxib and rofecoxib are examples of novel inhibitors 
that were developed from these binding studies which produce selective inhibition of 
COX-2 activity. 
 11 
FIGURE 1.2. Illustration of the cyclooxygenase pathway
 12 
COX-1 and COX-2 deficient mice 
The biological functions of the COX enzymes were originally hypothesized from 
in vivo and in vitro studies examining the pharmacological effects of NSAIDs. However, 
because of activity on non-COX targets, the lack of selectivity for an individual COX 
isoform, and only partial inhibition of either or both COX isoforms, the pharmacological 
effects of NSAIDs may not always reflect physiological or pathological functions of the 
COX isoforms. To better understand the physiological and pathological functions of the 
COX isoforms, mice deficient in either COX-1 or COX-2 were developed.
61-68
 Studies 
using these mice provided insight into the novel roles of both COX-1 and COX-2. These 
studies revealed that COX-1 in addition to COX-2 is involved in the development of 
various pathologies, whereas COX-2, in addition to COX-1 plays a significant role in 
development and the maintenance of homeostasis. 
Because COX-1 was traditionally thought to be responsible for maintaining 
housekeeping functions, it was surprising that the COX-1-deficient mice had very few 
phenotypic abnormalities.
61-63, 69
 The most unexpected finding was that these mice did not 
develop spontaneous gastric ulcerations, as it was thought that prostaglandins from the 
activity of COX-1 were responsible for maintaining the integrity of the gastric mucosa. 
Furthermore, these mice did not display kidney pathology and showed decreased ex vivo 
platelet aggregation without prolonged bleeding times in vivo. The most severe 
phenotype observed in the COX-1-deficient mice was the delayed onset of labor in 100% 
of the females. Studies by Tiano et al., using the COX-1-deficient mice showed that 
COX-1 plays an important role in skin tumorigenesis.
70
 Therefore, these knockout studies 
have determined that COX-1 is essential for providing only a limited number of house 
keeping functions but is capable of playing a significant role in pathological conditions.
61-
63, 66, 69, 70
 
In contrast to the COX-1-deficient mice, the COX-2-deficient mice exhibit overt 
phenotypes.
64
 All COX-2-deficient mice are born in the expected Mendelian ratios, 
however only about 65% of these mice survive up to weaning. Furthermore, the kidneys 
of these mice show a nephropathy, with poorly developed and reduced number of 
glomeruli, and pale and smaller kidneys. The female mice are infertile and have impaired 
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ovulation, implantation and decidualization.
71
 Thus, studies using the COX-2-deficient 
mice revealed that COX-2 plays an important role in normal physiological processes.
61-66
 
 
FACTORS REGULATING DA CLOSURE 
15-hydroxyprostaglandin dehydrogenase 
The dilation of the DA in utero is an active process maintained primarily by 
PGE2, circulating in the fetus.
72-75
 The placenta is a major source of PGE2 in the fetal 
circulation
76
 and traditionally it is thought that loss of this PGE2 source following birth, 
and the resultant decline in PGE2 levels, initiates contraction of the DA.
2
 PGE2 is 
catabolized into biologically inactive products by 15-hydroxyprostaglandin 
dehydrogenase (PGDH) and recently, mice deficient in PGDH were developed, and these 
mice exhibit a patent DA phenotype.
77
 Treatment of PGDH-deficient neonates with 
indomethacin, in the immediate postnatal period corrects the patent DA. Therefore, it was 
concluded that patent DA in PGDH-deficient mice resulted from elevated levels of PGE2 
after birth. It is known that PGDH expression increases late in gestation, particularly in 
fetal lungs.
78
 Because a majority of the fetal circulation is shunted away from the lungs 
through the DA; PGE2 is thought to be protected from being catabolized by PGDH in 
utero. However, after birth when the transition to pulmonary respiration occurs and blood 
flow to the lungs increases, PGE2 is broken down by PGDH, thereby resulting in a drop 
in PGE2 levels, and initiation of DA closure. 
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Figure 1.3. PGE2 maintains dilation of the DA in utero. 
The dilation of the DA in utero is active process maintained by primarily by 
PGE2, circulating in the fetus. The placenta is a major source of PGE2 in the fetal 
circulation. Loss of this PGE2 source following birth, together with induction of PGDH, 
the enzyme that catabolizes PGE2, is thought to initiate closure of the DA.  
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Cyclooxygenases 
To better understand the functions of both COX-1 and COX-2, we developed 
mice that were deficient in both enzymes. These mice were born alive in the expected 
Mendelian ratios, however 100% of these mice died within 12-24 hours after birth. After 
extensive pathological analysis, the only pathology that was found in these animals was a 
patent DA.
79
 Until our recent work, the predominant function of the COX isoforms 
expressed in the DA, was thought to be the synthesis of PGE2.
80, 81
 Numerous 
observations in humans and rodents indicate that maternal administration of NSAIDs 
constrict the DA in late-term fetuses.
82-85
 Therefore, the finding of patent DA in the 
COX-deficient mice was surprising because the lack of PG production in COX-deficient 
mice was expected to cause premature DA contraction, similar to the effects of NSAIDs. 
After the finding of patent DA in the COX-1/COX-2 double knockout mice, the COX-2-
deficient neonates were re-examined, and it was found that 35% of these mice also have a 
patent DA. Thus, our work using mice with targeted disruptions in the genes encoding 
COX-1 and COX-2 was the first report to identify a role for COX-2 in DA closure after 
birth. (Table 1) 
79
  
We extended these genetic studies to examine the effects of pharmacological 
inhibition, and found that specific inhibition of COX-2 during pregnancy also 
dramatically increases the incidence of patent DA in neonatal mice. (Table 1) 
86
 These 
findings are highly significant to human health because COX-2 inhibitors are currently 
being used in pregnant women in the United States and Europe to evaluate the efficacy of 
these medications for treatment of preterm labor.
87, 88
 Our work suggests that if the 
mechanisms of DA closure are conserved between species, the use of COX-2 inhibitors 
by women during pregnancy may impede normal closure of the DA after birth, thereby 
compromising neonatal health. We have also demonstrated that the DA expresses a 
greater level of COX-2 as compared to the adjacent aorta, suggesting the autocrine 
synthesis of vasoconstrictor prostanoids that may initiate DA closure after birth. 
However, to date, the identity of the specific COX-2-derived constrictor prostanoid or 
that of the specific contractile prostanoid receptor remains elusive.  
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Table 1. Incidence of patent DA with the genetic deficiency or pharmacological 
inactivation of COX-1 and/or COX-2 in mice.
79, 86 
Genetic deficiency of COX-2 results in patent DA in mice. This incidence increases when 
the gene copy number for COX-1 is reduced. Celecoxib treatment significantly increases 
patent DA incidence in neonates expressing COX-2 (*, P < 0.01, significantly different 
from vehicle treated). The patent DA incidence in the COX-2-deficient neonates 
following celecoxib administration does not increase significantly above the spontaneous 
patent DA incidence, indicating the selectivity of the drug for COX-2.  
 
                                                    Untreated                      Celebrex Treated
                                                                       Patent DA                     Patent DA
Offspring Genotype             % Incidence                 % Incidence           
COX-1(+/+)/COX-2(+/+)                          0                                        !                                          
COX-1(+/!)/COX-2(+/+)                          0                                        !
COX-1(!/!)/COX-2(+/+)                          0                                     100
COX-1(+/+)/COX-2(+/!)                          0                                        !
COX-1(+/!)/COX-2(+/!)                          0                                       79 
COX-1(!/!)/COX-2(+/!)                          0                                     100
COX-1(+/+)/COX-2(!/!)                        33
COX-1(+/!)/COX-2(!/!)                        74
COX-1(!/!)/COX-2(!/!)                      100                                                                    
                                                                   Patent Da % Incidence        
                                                                       
Offspring Genotype      Vehicle      Celecoxib        
COX-1(+/+)/COX-2(+/+)                          0                                      59*                                          
COX-1(+/!)/COX-2(+/+)                          0                                      70*
COX-1(!/!)/COX-2(+/+)                          0                                     100*
COX-1(+/!)/COX-2(+/!)                                                                 79*
COX-1(!/!)/COX-2(+/!)                          0                                     100*
COX-1(+/+)/COX-2(!/!)                        33     39
COX-1(+/!)/COX-2(!/!)                        74    77
COX-1(!/!)/COX-2(!/!)                      100                                            !                        
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Other factors regulating DA closure 
In addition to vasodilatory prostaglandins, nitric oxide has been known to have an 
accessory role in dilation of the DA. Nitric oxide is known to be a dilator of DA smooth 
muscle. Studies in the lamb DA have shown that nitric oxide donors such as sodium 
nitroprusside and glyceryl trinitrate, both of which increase intracellular concentrations of 
cGMP, are capable of dilating the DA.
2
 It has been shown previously in vitro that 
treatment of the DA with inhibitors of nitric oxide synthase, caused constriction of the 
DA, however the effect was minimum.
89
 Other studies have shown that treatment of the 
DA with inhibitors of nitric oxide synthase in combination with a COX inhibitor such as 
indomethacin, is more effective than either class of agents used alone.
90
 Thus, even 
though nitric oxide is involved in dilating DA in utero, it only plays an accessory role.  
Physiological increases in oxygen tension have been known to influence closure 
of the DA. It has traditionally been thought that a decrease in circulating PGE2 
concentrations after birth, together with an increase in arterial oxygen tension that 
follows the first breath, both trigger postnatal DA closure.
2
 Oxygen is known to increase 
intracellular calcium concentrations and cause contraction of DA smooth muscle. Studies 
in vitro have shown that treatment of the DA with antagonists for potassium and calcium 
channels, together with oxygen exposure resulted in inhibition of delayed rectifier 
potassium channels, causing membrane depolarization and increased entry of calcium, 
thereby resulting in DA constriction.
2
 Although potassium channels are involved in 
oxygen-dependent DA constriction, a role for this ion channel in contributing to patent 
DA has not been shown. Furthermore, studies in our laboratory have found that treatment 
of COX-1/COX-2 or COX-2 -deficient neonates with inhaled oxygen does not enhance 
DA closure.
86
 Thus, even though increased oxygen tension may normally be involved in 
DA closure, oxygen-dependent stimulation is not sufficient to produce DA closure in the 
absence of the COX isoforms.  
The SMCs and endothelial cells in the DA are known to synthesize endothelin-1 
(ET-1) and exogenous ET-1 is a potent constrictor of the DA. In vitro studies have shown 
that fetal DA synthesis of ET-1 is regulated by oxygen tension
2
, and ET-1 receptor type 
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A antagonists partially dilate DA constriction induced by oxygen.
91
 Although there are 
conflicting reports on the ability of ET-1 receptor antagonists to affect DA closure,
92, 93
 
the deficiency of the ET-1 receptor type A does not affect normal postnatal DA closure in 
mice.
94
  
 
PROSTANOID RECEPTORS 
Individual prostanoids act through specific membrane bound receptors to mediate 
their biological responses.
95-98
 To date, eight types of prostanoid receptors have been 
identified and are highly conserved between mice and humans. These receptors include: 
the PGD2 receptors, DP1, DP2 (CRTH2- chemoattractant receptor homologous 
molecule expressed on Th2 cells); the PGE2 receptors, EP1, EP2, EP3 and EP4; the 
PGF2" receptor FP, the prostacyclin receptor IP; and the TXA2 receptor TP.
97, 98
 All 
prostanoid receptors are G protein-coupled rhodopsin-type receptors with distinct 
intracellular signaling pathways (Table 2). Among these prostanoid receptors, DP, EP2, 
EP4 and IP have been termed as the relaxant receptors that mediate a rise in intracellular 
cAMP. Whereas, TP, EP1 and FP are termed the contractile receptors, as they contribute 
to calcium mobilization. EP3 is also considered a contractile receptor, but it mediates a 
reduction in cAMP levels, and thus is termed as an 'inhibitory' receptor. Mice deficient in 
each of these receptors have been developed and studies using these mice have revealed 
novel physiological and pathophysiological functions of prostanoids.
96, 98
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Table 2. Prostanoid receptors, signaling and vascular function. 
 
Prostanoid Receptor  Subtype Signaling Vascular 
Function 
PGD2 DP DP1 $ cAMP Dilation 
  DP2 
(CRTH2) 
% cAMP, Phospholipase C 
activation 
Undetermined 
PGE2 EP EP1 $ Ca
2+
 Constriction 
  EP2 $ cAMP Dilation 
  EP3 % cAMP Constriction 
  EP4 $ cAMP Dilation 
PGF2" FP  Phospholipase C activation, 
$ Ca
2+
 
Constriction 
PGI2 IP  $ cAMP Dilation 
TXA2 TP  Phospholipase C activation, 
$ Ca
2+
 
Constriction 
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Dilatory prostanoid receptors and the DA  
It is well known that the dilation of the DA in utero is an active process that is 
maintained by actions of PGE2. Therefore, most of the studies to date have focused on 
investigating the role of the PGE2 receptors in the regulation of DA dilation. Studies by 
Smith et al. examined the expression of the dilatory receptors in the rabbit DA using ex 
vivo techniques.
99
 These studies utilized pharmacological agonists and antagonists, to 
examine the effect of these drugs on dilation of the pre-constricted DA ex vivo. These 
studies showed that an agonist for the EP4 receptor was equipotent to PGE2 in dilating 
the DA, whereas the EP1 and EP3 agonist sulprostone, failed to mediate DA relaxation. 
Furthermore, an antagonist specific for the EP4 receptor blocked the dilatory effect of 
PGE2 on the DA. Therefore, it was concluded that the primary PGE2 receptor in the 
rabbit DA was EP4. However, studies by Nguyen et al., and Segi et al., showed that mice 
deficient in the EP4 receptor surprisingly had a postnatal patent DA phenotype.
100, 101
 
These findings suggested a role of PGE2 receptors other than EP4 in maintaining DA 
dilation and/or a novel previously unidentified function of EP4 that is required for DA 
closure. Studies by Smith et al., extended their findings to the ovine and baboon DA and 
found that EP3 and EP4 were expressed, however the expression of EP4 decreased with 
advancing gestational age.
102
 
Studies by Bhattacharya et al. examined the expression of the EP receptors in the 
porcine DA.
103
 These studies suggested that EP1 was not expressed in the porcine DA, 
but EP2, EP3 and EP4 were present. Furthermore, they suggested that the expression of 
EP3 and EP4 decreased with advancing gestation, whereas the expression of EP2 
remained unchanged. From these studies, it was concluded that the primary dilatory 
receptor in the porcine DA was EP2. This group extended their studies in the ovine DA 
and found that similar to the porcine DA, EP2, EP2 and EP4 were expressed in the fetal 
DA, whereas only EP2 was expressed in the newborn DA. Furthermore, stimulation of 
both EP2 and EP4 caused DA relaxation by mediating a rise in cAMP levels. They also 
suggested that although stimulation of the EP3 receptor caused a decline in cAMP levels, 
activation of this receptor produced DA relaxation. These studies were the first to suggest 
a role for the known contractile EP3 receptor in dilation of the ovine DA. The relaxant 
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effect of EP3 was attributed in part to the stimulation of KATP channels.
104
 A more recent 
study by Waleh et al., also examined EP receptor expression in the immature and mature, 
sheep and baboon DA.
105
 They found that in contrast to the studies by Smith et al.,
102
 the 
expression of EP4 remained unchanged in the DA, and EP2 was expressed in the DA at 
all stages of gestation. 
Thus, from the multitude of reports to date describing the various functions of EP 
receptor expression in the DA of different species, there have been several discrepancies 
in the findings. Although the significance of alterations in EP receptor expression has yet 
to be determined, the most consistent observation in the reports to date is the presence of 
the EP4 receptor in the DA and the ability of the DA to dilate in response to EP4-specific 
agonists. We have also recently shown that endogenous treatment of wild-type neonatal 
mice with an EP4-selective agonist, results in DA patency.
86
 So the question as to why 
the EP4-deficient mice exhibit a patent DA phenotype remains to be answered.  
A recent report by Yokoyama et al. has shed some light into this paradoxical 
finding of patent DA in EP4 knockout mice.
106
 These studies proposed an additional role 
for EP4, other that mediating DA dilation. First, they examined the expression of EP4 in 
the rat DA and found that EP4 expression significantly increased with advancing 
gestational age. Smooth muscle migration from the vascular media into the endothelial 
layer is an important vascular remodeling process involved in complete closure of the 
DA. These studies examined migration of the DA smooth muscle in response to EP4 
agonist stimulation and found that similar to the effects of PGE2, an EP4 agonist 
successfully resulted in migration of DA smooth muscle cells. Furthermore, they showed 
that EP4 stimulation resulted in induction of the hyaluronic acid gene. Hyaluronic acid is 
an important component of the extracellular matrix, and is involved in intimal cushion 
formation, and smooth muscle cell migration during DA remodeling. The DA of EP4-
deficient mice had reduced expression of hyaluronic acid. Thus, it was concluded that 
hyaluronic acid production is stimulated by EP4 receptor activation and production of 
this extracellular matrix component is an essential process in DA remodeling, without 
which, results in patent DA.
106
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Contractile prostanoid receptors and the DA  
Few studies have been reported to date, examining the effects of contractile 
prostanoids, and the characterization of contractile receptors in the DA. The prostanoid 
receptors known to mediate contraction of vascular smooth muscle are EP1, EP3, FP and 
TP. Studies by Smith et al., investigated the effects of agonists for the receptors on 
contraction of the rabbit DA ex vivo.
107
 The EP1/EP3 agonist, sulprostone, as well as the 
TP agonist U46619, caused concentration-dependent contraction of the DA, in the low 
nanomolar range, as examined by the isometric tension technique. The FP agonist had no 
effect on DA contraction, but in contrast caused DA relaxation at higher concentrations, 
which may be due to the non-specific binding of the agonist to other receptors. The 
endogenous ligand for EP1/EP3 is PGE2, and the primary effect of this ligand on the DA 
is known to be dilation. Therefore, it is not clear how the same endogenous ligand can 
have different effects on ductal tone when binding either the contractile or relaxant 
receptors. Furthermore, the authors themselves question these findings by saying that the 
contractile effects of sulprostone on the DA may have a non-specific effect by binding to 
either TP or other prostanoid receptors. Therefore, in these studies, it was concluded that 
the TP receptor might have a role in mediating DA contraction. 
We recently reported the endogenous effects of prostanoid receptor agonists on 
DA contraction in vivo. Mice that are deficient in both COX-1 and COX-2 show a 100% 
incidence of patent DA, and thus provide an advantageous model for examining the 
effects of different prostanoids or analogs on DA closure.
86
 COX-1/COX-2 double 
knockout mice were treated with sulprostone, an FP agonist, an EP4-specific agonist, 
PGE2, carbaprostacyclin (IP agonist), U46619 (a TP agonist and a PGH2 mimetic) or 
IBOP (TP agonist and TXA2 mimetic). Of all the compounds examined, only the two 
structurally distinct TP agonists, U46619 and IBOP, induce DA closure in the COX-
1/COX-2 double knockout mice in vivo, which is histologically indistinguishable from 
normal DA closure that occurs in wild-type mice. Treatment of COX-1/COX-2 double 
knockout mice with agonists selective for all other prostanoid receptors has no effect on 
DA closure. Thus, these studies suggest a role for the TP receptor in mediating DA 
closure. However, genetic deficiency of the only known TP receptor in mice does not 
alter DA closure
108
, suggesting the role for a novel prostanoid receptor in DA closure. 
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Furthermore, the possibility of an unidentified TP isoform has been suggested 
previously.
97, 109, 110
 Thus; it is possible that a currently uncharacterized contractile 
receptor is present, which may be responsible for mediating the actions of COX-2-
derived prostanoid(s) on the DA. 
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 METHODS 
Animals 
The wild-type mice used in these studies (8 to 10 weeks of age) were on a mixed 
background of C57BL/6J and 129/Ola and have been maintained by continuous 
intercrossing with mice from the same colony, as we have reported previously.
64, 65, 69
 
EP4 wild-type, heterozygous and homozygous -deficient mice were generated by 
crossing EP4 heterozygous mice that were backcrossed ten times to C57BL/6CrSlc 
(Japan SLC, Shizuoka, Japan). EP4 mutants were genotyped by PCR as previously 
described.
101
 The morning after pairing was designated as gestation day 0.5 upon 
detection of a copulation plug. Preterm wild-type mice were delivered by Cesarean 
section on gestation days 16 (82% gestation) or 17 (87% gestation). Full-term wild-type 
mice were delivered either by Cesarean section or natural birth on gestation day 19.5 
(100% gestation). Mice were housed under barrier conditions with food and water 
provided ad libitum. Experiments were conducted in accordance with the Institutional 
Animal Care and Use Committee at the University of Kentucky.  
 
Tissue Collection 
Mice for the 0 hour time point were euthanized immediately following birth 
whereas all mice that were be analyzed at the 3 hour time point, were placed in an 
atmosphere of 100% oxygen for the first 10 minutes following birth to improve survival. 
At the designated time points, animals were be euthanized in a CO2 chamber followed by 
thoracotomy, to expose the heart and great vessels. The DA extends from the main 
pulmonary artery and connects to the proximal descending aorta just after the origin of 
the left subclavian artery. DA tissue was excised carefully without contamination of 
surrounding vessels, and lysed immediately in tissue lysis buffer from the RNA isolation 
kit.  
 
RNA Isolation 
Total RNA was isolated from tissues using the RNAqueous Kit from Ambion, 
which uses a modified version of the traditional Chomczynski and Sacchi method.
111
 The 
RNAqueous method utilizes the ability of nucleic acids in concentrated chaotropic salt 
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solutions, to bind glass fibers. DA tissue was first lysed in a glass micro-mortar and 
pestle apparatus, using a buffer containing a high concentration of guanidium salt, which 
also inactivates RNAses. The lysate was then diluted with an ethanol solution, which 
allowed the RNA to bind the glass fibers in the filter cartridge. The solution was passed 
through the filter cartridge, and the filter pad, where the RNA remained bound while the 
other cellular components flowed through. The filter cartridge was washed 3 times using 
wash buffer to allow removal of contaminating materials. RNA was then eluted using a 
hot elution solution of low ionic strength. RNA concentrations were measured using the 
Nano Drop system.  
 
cDNA Preparation 
Total RNA (~150 ng per DA) was reverse transcribed using the following 
components: random hexamers, 10X reverse transcription buffer, deoxynucleotide 
triphosphate mix (dNTPs), RNAse inhibitor, and Superscript II reverse transcriptase. The 
reverse transcription was carried out using a thermal cycler (Eppendorf) with the 
following conditions: RNA + hexamers + dNTPs at 65°C for 5 min followed by placing 
the mixture on ice for 5 min. This was followed by addition of the remaining components 
to the tube and back into the thermal cycler for the following conditions: 25°C for 10 
minutes, 42°C for 50 minutes and 70°C for 15 minutes to terminate the reaction. This 
cDNA was stored at -20°C until utilized for gene expression analysis. 
 
Quantitation of mRNA expression 
Gene expression quantitation was performed in a two-step RT-PCR (ABI Prism 
7000 system) in which the PCR step is coupled with fluorogenic 5' nuclease chemistry 
(Taqman chemistry). Primer/probe assays for COX-1, COX-2, EP2, EP3, EP4, and TP 
were purchased from Applied Biosystems (Foster City, CA). mRNA encoding the 
housekeeping gene, hypoxanthine phospho-ribosyl transferase (HPRT) was also 
quantitated for an internal normalizing control.
112
 There was no significant difference in 
HPRT mRNA levels throughout gestation, when compared to other housekeeping genes 
(data not shown). A relative standard curve using cDNA from TPA-treated skin or lung 
tissue was run within the same reaction. The quantity of mRNA for the gene of interest 
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was extrapolated from its respective standard curve, followed by normalization with the 
HPRT levels. Because the expression analysis for each gene of interest was performed on 
separate reaction plates, and because the primers for each gene of interest were of 
different efficiencies, comparison of expression levels between genes of interest was not 
performed.  
 
 
Histology 
At the designated time points, neonates were sacrificed followed by fixation of 
torsos in 10% neutral buffered formalin. As we have described previously
79, 86
, upper 
torsos were transected above the rib cage and processed (paraffin embedded) for 
histological analysis. Analyses were performed on transverse sections of the upper 
thorax. The entire length of the DA from the descending aorta to the bifurcation of the 
pulmonary arteries was serial sectioned, followed by immunohistochemical analysis for 
COX-2 (primary antibody from Cayman Chemical, Ann Arbor, MI), smooth muscle cell 
marker "-actin (Dako Cytomation, Carpentaria, CA), endothelial cell marker PECAM 
(Santa Cruz) and the intermediate filament protein, desmin (Chemicon). Antigen retrieval 
was carried out in citrate buffer by heating to 96°C in a microwave oven, followed by 
cooling for 20 min at room temperature. Sections were first blocked with 1% BSA, 1% 
nonfat dried milk, and 1% normal serum. Incubations with the primary antibodies were 
carried out overnight at room temperature in a humidity chamber. Antibody binding was 
detected using the Vectastain Elite ABC kit (Vector laboratories, Burlingame, CA), using 
the manufacturer's instructions. DA sections were also stained with hematoxylin (H) and 
eosin (E) for morphological analysis of DA closure.  
 
Statistics 
Data are expressed as mean ± SEM. Data were analyzed using GraphPad Prizm 
software and tested for normality. Statistically significant differences in the expression of 
COX-1, COX-2, EP2, EP4 and TP, at multiple stages of gestation were determined by 
one-way ANOVA. Two-way ANOVA was utilized in the measurement of gene 
expression differences between the DA and aorta, at different time-points. Unpaired 
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Student's t-test was used to determine difference of means in the experiments involving 
gene expression at 2 different time-points after birth, or two different gestational time-
points.  
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CHAPTER 2 
CHARACTERIZATION OF THE CELL TYPES IN THE MOUSE DA  
 
Introduction 
Morphology of the DA. 
The wall of the DA is composed of three layers: 1) The intima which is comprised 
of endothelial cells 2) intimal cushions which consist of cellular and elastic layers 
between the endothelial cells and the internal elastic lamina and 3) the medial layer which 
consists of SMCs which are oriented longitudinally, circularly and spirally. At early 
gestation, the medial SMC layer in the DA is similar to that of the adjacent great vessels. 
In order to achieve permanent closure after birth, the DA develops in utero such that it 
acquires a highly muscular phenotype. With advancing gestation, the intimal cushions in 
the DA progressively become thicker than those in the adjacent arteries. The internal 
elastic lamina becomes fragmented and prominent and thin layers of elastin and collagen 
line the layers in the intimal cushions.
4
 
 
Differences between the DA and Adjacent Great Vessels. 
Despite the similarities between the developmental origin of the DA and adjacent 
arterial beds, the DA unlike its neighboring arteries, becomes highly muscular as 
development progresses. Even though the internal lamina of the DA consists of an elastin 
layer, as compared to the adjacent arteries, the DA has significantly less elastin.
4, 5, 113
 In 
normal vascular smooth muscle, two types of smooth muscle type myosin heavy chain 
isoforms SM1 and SM2, and two other non-muscle type MHC isoforms are expressed. Of 
the two smooth muscle type isoforms, SM2 is associated with the contractile phenotype 
of SMCs. Several studies have shown that as compared to the adjacent aorta and 
pulmonary artery, the DA expresses a greater level of SM2.
4, 114, 115
 The increased 
expression of SM2 in the DA as compared to the adjacent great vessels is thought to 
contribute to the contractile nature of DA smooth muscle. Furthermore, myofilament 
structures, indicative of contractile function, were more abundant in the DA as compared 
to adjacent vessels.
4
 Studies in our laboratory (unpublished) as well as by others have 
shown that expression of the intermediate filament protein desmin, indicative of the 
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advanced differentiation and development of contractile function, is greater in the DA of 
mice, as compared to adjacent aorta.
4
 Thus, the DA is a muscular artery, which consists 
of highly differentiated SMCs and possesses a contractile machinery which is unique to 
this artery.  
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Results 
We utilized the mouse DA as a model for studying the morphology of this vessel. 
We employed the periodic acid/Schiff's staining method to identify the basement 
membrane and to distinguish between the layers of cells in the DA. As shown in figure 
2.1, the DA is comprised of multiple layers of cells. The media of the DA is primarily 
formed of smooth muscle cells (Figure 2.2). The inner media appears to be comprised of 
radially oriented smooth muscles cells, whereas the middle and outer layers of the media 
contains more closely packed, circularly oriented smooth muscle cells. These medial 
smooth muscle cells are encompassed with a layer of fibroblast like cells in the 
adventitia. Endothelial cells comprise the inner lining of the intimal layer, as shown in 
Figure 2.3. The formation of intimal cushions has been thought to be an important event 
in remodeling of the DA. When comparing figures 2.2 and 2.3, it appears as if the 
endothelial cells have separated from the internal elastic lamina, and smooth muscle cells 
have migrated to occlude the lumen. Progressive development of the intimal cushions is 
accompanied by fragmentation of the internal elastic lamina, as shown in (Figure 2.4). In 
contrast, in the patent DA, the internal elastic lamina appears to be intact with apparent 
distinct layers (Figure 2.5). 
We also examined expression of the contractile filament protein desmin in the DA 
and the adjacent vessels. Our studies show that the DA expresses a dramatically greater 
level of desmin in the SMCs of the DA as compared to SMCs of the aorta and adjacent 
arteries (Figure 2.6). This increased desmin expression contributes to the contractile 
nature of the DA, as opposed to the neighboring elastic arteries.  
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Figure 2.1 Basement membrane staining 
This figure represents a completely remodeled DA, from a neonatal mouse at 3 
hours after birth. Sections were stained with periodic acid/Schiff reagent (Newcomer 
supply).  
 
 
      
Basement membrane 
 
                                     
                                  DA                                                     Ao
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Figure 2.2 Smooth muscle cell staining 
Slides were stained with an antibody against "-actin, which is a marker of smooth 
muscle cells. The slides are counter stained with periodic acid/Schiff's reagent, which 
allows distinguishing between the different layers of cells. Brown staining (DAB reagent) 
indicates smooth muscle cells.  
 
 
 
Basement membrane 
 
 
                                       Smooth muscle cells 
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Figure 2.3 Endothelial cell staining 
 
Slides were stained with an antibody against PECAM, which is a marker of 
endothelial cells. As shown in the figure, it is apparent that the endothelial cells (as 
indicated by the brown staining) have detached from the internal elastic lamina, and have 
segregated in the lumen.  
 
 
 
 
 Endothelial cells 
 
Basement membrane 
 
 
 34 
Figure 2.4 Elastin staining 
 
 
 Closed DA                                                         Patent DA  
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Figure 2.5 Desmin staining 
 
Sections were stained with an antibody against the contractile filament protein, 
desmin. The brown staining (DAB reagent) indicates greater desmin expression in the 
DA as compared to the adjacent aorta. Figures shown are representative of DA from a 
minimum of 5 mice. DA, ductus arteriosus, Ao, descending aorta.  
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CHAPTER 3 
ANALYSIS OF INDOMETHACIN-INDUCED CONSTRICTION OF  
THE DA IN UTERO 
 
Introduction 
The role of PGs in the regulation of DA tone was initially determined from the 
observation that NSAIDs such as indomethacin modulate DA tone following birth. The 
dilation of the DA in utero is active process maintained by prostaglandins PGs, primarily 
PGE2, circulating in the fetus. The placenta is thought to be the major source of the 
circulating PGE2 in the fetus. It has been shown that in humans and rodents, maternal 
administration of indomethacin results in the reduction of the circulating PGE2 levels, 
possibly by inhibiting the placental PGE2 source, thereby resulting in DA constriction.
2
 
Studies in sheep and rats have shown that maternal administration with 
indomethacin, late in gestation results in premature constriction of the fetal DA.
82-85
 
Similar to the effects of indomethacin, we and others have shown previously, that the 
COX-2-selective inhibitor, celecoxib, when administered acutely to late gestation fetuses 
in utero, results in premature constriction of the fetal DA.
86, 116
 In contrast to the effect of 
the COX inhibitors on late gestation fetuses, studies have shown that the preterm fetuses 
are less responsive to the constricting effects of COX inhibitors.
82, 117
 This suggests that 
the development of the DA with advancing gestation may be related to the contractile 
function of the DA. In the current studies, we utilized maternal indomethacin treatment as 
a method to investigate the relationship between the ontogeny of the DA and the 
development of DA contractile function.  
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Results 
It is known that the DA of fetuses remains patent, thereby allowing the blood flow 
in the heart to bypass the uninflated lungs. We examined DA closure in mouse fetuses on 
gestation day 18.5 following maternal treatment with vehicle. Similar to our previous 
findings, the DA of fetuses treated with vehicle in utero, was completely patent. (Figure 
3A) 
As we have previously reported, we utilized indomethacin treatment to examine 
the ability of the fetal DA to close prematurely. Indomethacin was administered to 
pregnant female mice on gestation day 18.5. Four hours after dosing, fetuses were 
analyzed for premature DA constriction by histology. As compared to the completely 
patent DA of vehicle-treated controls (Figure 3A), indomethacin treatment induced 
complete occlusion of the DA of late term fetal mice on gestation day 18.5 (Figure 3B). 
We also utilized indomethacin treatment to examine the ability of the DA of 
preterm fetuses to contract in utero. Our results show that in contrast to the DA of late 
gestation fetuses, indomethacin resulted only in partial constriction of the preterm fetal 
DA of mice on gestation day 16 (Figure 3C). These studies show that in mice, the 
preterm gestation fetal DA is less responsive to pharmacologically-induced constriction, 
and suggest that near full-term maturation is required for complete development of DA 
contractile function.  
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Figure 3  
Incomplete indomethacin-induced constriction of the DA in preterm fetal 
mice. Indomethacin was administered to pregnant dams on gestation day 16 or 18.5 (50 
mg/kg, oral gavage 5% gum arabic). Four hours after dosing, fetuses were delivered by 
Cesarean section and sacrificed for DA analysis. n & 5 per group. DA, ductus arteriosus, 
Ao, descending aorta. DA of fetal mice treated with vehicle A) or indomethacin B) on 
gestation day 18.5. C) DA of fetal mice treated with indomethacin on gestation day 16. 
Sections are stained with H&E.  
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Discussion 
Fetal DA constriction induced by the non-selective COX inhibitor indomethacin 
has long been used to study pharmacologically-induced contractile responses in the 
DA.
105, 118
 Maternal treatment with the non-selective COX inhibitor indomethacin, is 
known to induce two paradoxical effects on the DA. In both humans and rodents, 
maternal administration of indomethacin results in premature constriction of the DA by 
inhibiting the synthesis of prostanoids important for DA dilation.
2, 85, 117
 Alternatively, it 
has also been shown that indomethacin treatment during pregnancy can increase the risk 
for postnatal patent DA.
119-121
 Our recent report has shown that similar to previous studies 
with indomethacin, acute administration of a COX-2-selective inhibitor but not a COX-1-
selective inhibitor, results in premature constriction of the DA.Whereas chronic 
administration with a COX-2-selective inhibitor, results in postnatal patent DA.
86
 A 
recent report by Reese et al., replicated our findings in mice and showed similar 
results.
122
 The contrasting effects of COX-2 inhibition that we showed recently, and the 
paradoxical effects of indomethacin shown by others, suggest opposing actions of 
different prostanoids on the regulation of DA tone. The dilation of the DA in utero is 
active process maintained by prostaglandins PGs, primarily PGE2, circulating in the fetus. 
The placenta is thought to be the major source of the circulating PGE2 in the fetus. 
Therefore, it is possible that the constriction of the DA that is observed following acute 
administration of indomethacin or a COX-2-selective inhibitor results from the reduction 
of circulating PGE2 levels by inhibiting COX activity in the placenta. In contrast, the 
patent DA observed with indomethacin treatment or with chronic treatment with a COX-
2 inhibitor may be due to sufficient inhibition of synthesis of contractile prostanoids 
produced by COX-2 in the DA. Although we do not completely understand the two 
opposing effects on the DA resulting from indomethacin treatment, particularly at the 
time of peak COX-2 expression, nonetheless we can use this agent as a convenient 
functional marker for the ability of COX-2 to induce DA closure.  
Previous studies in rats and humans have shown that the preterm fetal DA is less 
responsive to indomethacin-induced constriction, in contrast to the DA of full-term 
fetuses.
82, 117
 In the current studies, we examined the effect of gestational age on 
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indomethacin-induced fetal DA constriction in mice. Our results show that the preterm 
fetal DA on gestation day 16 was less responsive to the constricting effects of 
indomethacin, as compared to the late gestation fetal DA on day 18.5. Therefore, in mice 
the contractile nature of the DA develops late in gestation.  
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CHAPTER 4 
ANALYSIS OF COX-1 AND COX-2 EXPRESSION IN THE FETAL AND 
NEONATAL MOUSE DA 
Introduction 
Previous studies in higher species such as pigs and sheep, have examined the 
developmental regulation of the COX isoforms in the DA. Studies by Guerguerian et al., 
measured COX-1 and COX-2 expression in fetal and newborn porcine DA and 
determined that COX-1 expression was constitutive in the fetal and newborn DA.
80
 In 
contrast, COX-2 expression was only detected in the newborn DA. They also examined 
the relative contribution of the COX isoforms in the synthesis of PGE2 and found that 
COX-2 was responsible for synthesizing greater than 90% of PGE2 in the newborn DA. 
Based on these findings, Guerguerian et al. concluded that COX-2 does not play a role in 
regulating DA tone after birth. 
Another study by Clyman et al., examined the expression of the COX isoforms in 
the late-gestation fetal lamb DA.
1
 These studies suggested that both COX-1 and COX-2 
were expressed in the fetal lamb DA. The expression of COX-1 was detected in the 
endothelial cells lining the DA lumen, as well as the smooth muscle cells of the media. 
However, COX-2 expression was only detected in the endothelium lining the DA lumen. 
These studies also examined the relative contributions of COX-1 and COX-2 for PGE2 
synthesis, using selective inhibitors of each isoform, and suggested that both COX 
isoforms contributed equivalently to the production of PGE2 in the DA. 
 
A more recent study by Baragatti et al. examined the expression of the COX 
isoforms in the full-term gestation fetal mouse DA.
123
 They showed that both COX-1 and 
COX-2 mRNA were expressed in the DA of full-term fetal mice. These studies also 
suggested that COX-2 co-localized with microsomal PGE2 synthase-1, an enzyme 
downstream of the COX isoforms, which converts the intermediate prostanoid PGH2 into 
PGE2. Based on these findings, Baragatti et al. suggested that in the full-term fetal DA, 
COX-2 is the isoform responsible for synthesizing PGE2. 
Recently, studies by Rheinlaender et al. examined COX isoform expression in the 
human DA and suggested that COX-1 is the predominant isoform expressed in the DA 
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throughout gestation, whereas the expression of COX-2 was weak.
124
 These studies also 
suggested that that the cellular expression pattern of the COX isoforms changed with 
advancing gestation. 
All these previous reports have focused on the role of the COX enzymes in 
synthesizing PGE2 important for DA dilation. Furthermore, there are several 
discrepancies regarding the expression of the COX enzymes in the fetal DA. The factors 
involved in ontogenic changes in COX expression seem to vary between tissues and cells, 
and thus far remain elusive. Our previous studies have shown that about 35% of mice 
genetically deficient in COX-2 show a postnatal patent DA and resulting mortality. The 
patent DA incidence increases as the gene copy number for COX-1 and COX-2 
decreases, reaching a 100% in mice doubly deficient in both COX-1 and COX-2.
65, 79
 We 
extended these findings and showed that wild-type neonatal mice born after exposure of 
pregnant mice with a COX-2 selective inhibitor, show an increased postnatal patent DA 
incidence.
86
 These studies indicated the importance of COX-2-derived prostanoids in 
postnatal closure of the DA. Our studies were the first to suggest that COX-2-derived 
prostanoid(s), other than PGE2 play an active role in closure of the DA after birth. 
Our previous studies also indicated the importance of COX-2 in constriction of 
the DA in utero. We utilized indomethacin treatment to assess the ability of the fetal DA 
to constrict. Our studies showed that all fetuses genetically deficient in COX-2 were 
resistant to indomethacin-induced premature DA constriction.
79
 This suggested that the 
expression of COX-2 is required for the contractile function of the DA in utero. In the 
current studies, we examined the expression of COX-1 as well as COX-2 in the fetal DA 
at multiple stages of gestation, as well as the neonatal DA at full-term gestation. These 
studies will provide a better understand of the role of the COX isoforms in DA closure 
after birth.  
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Results 
Expression of COX-2 mRNA in the fetal DA at multiple stages of gestation.  
We examined the time-course of COX-2 expression in the DA of fetal mice at 
multiple stages of gestation. To perform these studies, fetuses were obtained by Cesarean 
section on days 16, 17 and 19.5 of gestation, and DA tissue was excised immediately (0 
hours) for analysis of mRNA expression. Comparative quantitative analysis of COX-2 
mRNA expression showed that COX-2 expression significantly increased with advancing 
gestation, with the highest expression in the DA on day 19.5 (Figure 4.1). Furthermore, 
the gestation day 16 time-point with the lowest level of COX-2 mRNA coincided with 
the time at which we observed incomplete indomethacin-induced constriction of the fetal 
DA (Figure 3C). These data demonstrate a correlation between reduced DA constriction 
and attenuated COX-2 expression in the DA of preterm mice.  
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Figure 4.1  
Expression of COX-2 increases in the fetal DA with advancing gestation. 
Preterm (gestation days 16 and 17) and full-term (gestation day 19.5) mice were 
obtained at 0 hr (sacrificed immediately after birth) for analysis of mRNA expression for 
COX-2 in the DA by real-time PCR. The housekeeping gene HPRT was used as an 
internal control for normalizing mRNA levels. Data represented as mean COX-2 mRNA 
levels +/- SEM. **, significantly different from 0 hour day 16, P < 0.01 (one-way 
ANOVA), n & 10. ***, significantly different from 0 hour day 16 and 0 hour day 17, P < 
0.001 (one-way ANOVA), n & 10  
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Expression of COX-1 mRNA in the fetal DA at multiple stages of gestation.  
We also quantitated COX-1 mRNA expression in the DA on gestation days 16, 17 
and 19.5 of gestation. We found that in contrast to COX-2 expression, the expression of 
COX-1 did not significantly change with advancing gestational age (Figure 4.2). This 
finding suggests that alterations in COX-1 mRNA expression are not associated with in 
utero development of fetal DA contractile function.  
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Figure 4.2 
Expression of COX-1 remains constitutive in the fetal DA with advancing gestation. 
Preterm (gestation days 16 and 17) and full-term (gestation day 19.5) mice were 
obtained at 0 hr (sacrificed immediately after birth) for analysis of mRNA expression for 
COX-1 in the DA by real-time PCR. The housekeeping gene HPRT was used as an 
internal control for normalizing mRNA levels. Data represented as mean COX-1 mRNA 
levels +/- SEM. 
 
 
 
 
 
 
 48 
Analysis of COX-1 and COX-2 expression in the DA of neonatal mice at full-term 
gestation 
We examined COX-2 mRNA expression in the DA of full-term neonates, 
immediately after birth (0 hours) when the DA was patent, and 3 hours after birth when 
the DA was completely closed. Quantitative real-time PCR analysis indicated that COX-2 
mRNA dramatically increased (approximately 10 fold) in the DA when compared 
between 0 and 3 hours after birth on gestation day 19.5 (Figure 4.3-A). This increase in 
COX-2 mRNA expression from 0 to 3 hours after birth was unique to the DA, as no such 
increase in COX-2 expression was observed in the adjacent aorta. We also examined 
COX-2 protein expression by immunohistochemistry and found that significant COX-2 
protein was localized in the smooth muscle cells of the DA with evidence of perinuclear 
expression, but not in the smooth muscle cells of the adjacent aorta (Figure 4.3-B). 
Therefore, a significant increase in smooth muscle cell expression of COX-2 
accompanies closure of the DA after full-term birth.  
We also compared COX-1 expression in the full-term neonatal mouse DA 
between 0 and 3 hours of birth. In contrast to COX-2 expression, the expression of COX-
1 mRNA was constitutive with no significant difference between the two time-points 
(Figure 4.3-C).  
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Figure 4.3 
Induction of COX-2 expression in the DA of full-term neonatal mice.  
A) Full-term mice were delivered by Cesarean section or natural birth on 
gestation day 19.5 and sacrificed at 0 or 3 hours after birth for analysis of COX-2 mRNA 
in the DA or aorta. Data represented as mean COX-2 mRNA levels +/- SEM. *, 
significantly different from 0 hour DA and 3 hour Ao. P < 0.001 (two-way ANOVA), n & 
10. B) Immunohistochemical analysis of COX-2 expression. Full-term mice were 
delivered by Cesarean section or natural birth on gestation day 19.5 and sacrificed at 2 or 
3 hours after birth. Brown staining (di-amino benzidine, DAB) indicates COX-2 
expression. Figure shown is representative of neonatal DA from a minimum of 5 mice 
after 2 hours of birth. Inset shows perinuclear staining. DA, ductus arteriosus, Ao, 
descending aorta. C) Real-time PCR analysis of COX-1 mRNA expression in the DA at 0 
and 3 hours after birth on gestation day 19.5. Data represented as mean COX-1 mRNA 
levels +/- SEM.  
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Discussion 
Several groups have examined the developmental regulation of the COX isoforms 
in the DA in multiple species. There have been significant inconsistencies in these 
reports, showing that either COX-2 is not expressed, is expressed weakly or increases 
during gestation.
1, 80, 123
 Furthermore all these reports together focus on the role of COX-2 
in synthesizing the dilatory PGE2 responsible for maintaining a dilated DA in utero and 
suggest that the withdrawal of the dilatory PGE2 after birth may allow for DA closure. It 
is also suggested that COX-2 does not play a role in regulating DA closure after birth. 
These studies by other groups investigating the ontogeny of the COX isoforms in the 
DAs of other species do not explain our findings of the role of COX-2 in mediating DA 
closure. The present investigation was carried out to resolve the apparent inconsistencies 
in previous reports and gain, at the same time, a better insight into the functional 
organization of the COX enzymes in the DA.  
We have previously reported that the DA of COX-2-deficient fetuses fails to 
constrict in response to indomethacin, suggesting the importance of COX-2 expression 
for in utero contractile function.
79
 Therefore, in the current study, we investigated the 
relationship between the ontogeny of COX-2 expression and the developmental 
regulation of fetal DA constriction. COX-2 expression in the DA was significantly 
greater in full-term fetuses than that in preterm fetuses. Our previous report, together with 
our current study suggest that the contractile function of the DA that develops towards 
the end of term requires the in utero increase in COX-2 expression with advancing 
gestational age. 
The factors responsible for inducing normal closure of the DA after birth have not 
been clearly defined. Our previous studies using mice deficient in COX-2, clearly 
demonstrate the importance of this enzyme in postnatal DA closure. In mice, DA closure 
commences within 30 minutes after full-term birth, and is complete by 3 hours after birth. 
We have found that that COX-2 expression is induced in the neonatal DA at 3 hours after 
birth following full-term gestation, which coincides with the time at which the DA is 
completely remodeled. Thus, the induction of COX-2 in the DA may be required for 
normal closure of the DA after birth.  
The induction of COX-2 that we observe in the DA is unique to this vessel, as no 
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such increase is observed in the adjacent vessels such as the aorta. This suggests that 
autocrine production of prostaglandins in DA actively mediates DA closure. The vascular 
remodeling process involving intimal thickening, that occurs during closure of DA, are 
similar to the processes that occur in pathological process such as atherosclerosis and 
restenosis.
125
 In such pathological conditions, it has been reported previously that COX-2 
is significantly induced in the aorta. This induction of COX-2 in the aorta during 
atherosclerosis is associated with increase in production of prostanoids such as PGE2 and 
TXA2, together with macrophage accumulation and recruitment of inflammatory 
cytokines and chemokines.
126-128
 A recent study by Waleh et al. showed that similar to 
atherosclerosis, macrophage accumulation in the vessel wall plays an important role in 
DA remodeling.
10
 They found that this macrophage accumulation is associated with the 
induction of cytokines and adhesion molecules, and the extent of neointimal remodeling 
is directly related to the degree of mononuclear cell adhesion. Thus, the DA provides a 
physiological model of vascular remodeling, and studies on the DA may provide further 
insight into the development of treatments for vascular pathologies such as 
atherosclerosis.  
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CHAPTER 5 
ANALYSIS OF POSTNATAL DA CLOSURE AND COX EXPRESSION AT 
PRETERM AND FULL-TERM GESTATION IN MICE 
 
Introduction 
The initial phase of closure of the DA involves a contraction of its thick muscular 
wall. This is followed by anatomical remodeling of the vessel, which includes migration 
of the smooth muscle cells into the sub-endothelial space, creating intimal cushions. 
Following remodeling of DA SMC, significant apoptosis and cytolytic necrosis are 
thought to be required for complete obliteration of the DA. DA closure in humans is 
complete within a few days after birth. However, in other species such as mice, rats and 
rabbits, DA closure is complete within a few hours after birth. After permanent closure of 
the DA, a remnant of the vessel remains, which is known as the ligamentum arteriosum, 
which is formed by fibrosis of the closed vessel.
12
 
The factors responsible for inducing normal closure of the DA after birth have not 
been clearly defined. Our previous studies using mice deficient in COX-2, clearly 
demonstrate the importance of this enzyme in postnatal DA closure. In mice, DA closure 
commences within 30 minutes after full-term birth and is complete within 3 hours. Our 
current studies show that COX-2 expression is dramatically induced in the neonatal DA 
within 3 hours of birth at full-term gestation, which correlates with the time-point when 
the DA is completely remodeled. This suggests that induction of COX-2 expression in the 
DA may be required for achieving permanent closure after full-term birth. 
In humans, the incidence of patent DA is increased at premature gestation, 
however the mechanisms responsible for this increased incidence are not clear. Our 
previous study utilized indomethacin treatment as a functional marker of constriction of 
the DA in utero. We showed that the DA of premature fetuses failed to completely 
constrict in response to indomethacin, as opposed to the DA of full-term fetuses. We also 
examined the ontogeny of COX isoforms in the fetal DA at multiple stages of gestation. 
We found that the time-point of gestation when the DA of preterm fetuses failed to 
constrict in response to indomethacin, coincided with the time-point at which the 
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expression of COX-2 in the DA was the lowest. This suggests that the failure of DA to 
constrict prematurely may be due to a reduced expression of COX-2.  
In the current study, we utilized the mouse to establish a model of postnatal patent 
DA resulting from prematurity in gestation. To date, there has no animal model 
established to study the mechanisms of DA patency at preterm gestation. Because our 
previous study showed that the preterm gestation fetuses show incomplete indomethacin-
induced constriction, we hypothesized that neonatal mice born at preterm gestation may 
also show a post-natal patent DA. Furthermore, we compared the expression of COX-1 
and COX-2 in the DA from preterm and full-term neonatal mice. We hypothesized that 
similar to our observations in preterm fetal mice, the DA of preterm full-term neonatal 
mice will show attenuated COX-2 expression. 
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Results 
Morphological analysis of DA closure at 0 and 3 hours after birth at full-term gestation 
As shown in Figure 5.1, we found that that the DA was completely patent in 
neonatal mice at 0 hrs after birth at full-term gestation. This was indicated by the blue 
dye flowing through the widely open DA, with its diameter being similar to that of the 
adjacent aorta. The DA was completely occluded in neonatal mice at 3 hours after birth 
on gestation day 19.5. This was indicated by end of the blue dye at the point where the 
pulmonary artery ended and the DA began. The opaque white tissue is indicative of a 
completely closed DA.  
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Figure 5.1. Morphological Analysis of DA Closure 
A) The DA of a neonatal mouse, analyzed immediately after birth. The blue dye 
passing through the DA is indicative of DA patency. B) The DA of a neonatal mouse 
analyzed 3 hours after birth. The failure of the blue dye to pass through the DA is 
indicative of a closed DA. Arrow, DA. 
 
                 Patent DA                                                          Closed DA 
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Histological analysis of DA closure at 0 and 3 hours after birth at full-term gestation 
We also analyzed DA closure in mice using histological techniques. When 
analyzed at 0 hours after birth on gestation day 19.5, the DA was completely open, with 
no evidence of neointimal thickening, and the diameter of the vessel wall being similar to 
that of the adjacent aorta. (Figure 5.2A) In contrast, the DA was completely remodeled in 
all neonates sacrificed at 3 hours after birth at full-term gestation. (Figure 5.2B) This was 
indicated by significant neointimal formation and complete obliteration of the vessel 
lumen.  
 
Histological analysis of DA closure at 3 hours after birth at preterm gestation 
Our studies confirmed that the DA of mice born at full-term gestation closes 
completely at 3 hours after birth. In this study, we wanted to examine the effect of 
prematurity in gestation on DA closure in mice. In order to successfully accomplish these 
studies, it was important to determine the survival incidence of mice born at preterm 
gestation, and to ensure that the survival incidence was comparable to that of full-term 
gestation mice. Based on our previous studies, we know that the survival incidence of 
full-term wild-type neonates delivered by Cesarean section on day 19 is approximately 
98%. To determine the survival incidence of preterm wild-type neonates, we delivered 
litters on gestation day 17.5 by Cesarean section. The neonates were placed in an 
atmosphere of 100% oxygen for the first 10 minutes following birth and exposed to 
tactile stimulation using a vibrating heating pad and monitored for up to 5 hours after 
birth. A survival incidence of 83% (19/23) was observed in these preterm neonates. This 
level of survival was acceptable for the studies to examine the effect of prematurity on 
DA closure.  
Our findings indicate that in contrast to the complete DA closure observed in all 
neonates analyzed at 3 hours after full-term birth on day 19.5, significant lumen was 
visible in the DAs of all preterm neonates that were analyzed at 3 hours after birth on 
gestation day 17 (Figure 5.2C). These findings indicate that the DAs of neonatal mice 
born premature show incomplete closure. 
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Figure 5.2 Histological Analysis of DA Closure 
A) This figure is a representative transverse section of a completely patent DA of 
neonatal mice immediately after birth at full-term gestation. B) This panel is a 
representative transverse section of a completely closed DA of neonatal ice, 3 hours after 
birth at full-term gestation on day 19.5. C) Representative transverse section of an 
incompletely closed DA from neonatal mice, 3 hours after birth at preterm gestation on 
day 17. Sections are stained with H&E. DA, ductus arteriosus, Ao, descending aorta.  
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Figure 5.2. Histological analysis of DA closure.  
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Postnatal expression of COX-1 and COX-2 in the DAs of preterm neonatal mice.  
To determine whether the incomplete closure of the DA in preterm neonatal mice 
that we observed (Figure 5.2) was associated with attenuated expression of COX-2, we 
compared COX-2 expression in the DA between preterm (day 17) and full-term (day 
19.5) neonates at 3 hours after birth. In comparison to the level of expression observed in 
the DAs of full-term neonates, COX-2 mRNA expression in the DAs of preterm 
neonates, was significantly lower (Figure 5.3A). The attenuated COX-2 expression 
coincided with the time-point at which we observed incomplete closure of the DA at 
preterm gestation (Figure 5.2C). In contrast to COX-2 expression, there was no 
significant difference in COX-1 mRNA expression between DAs from preterm and full-
term neonatal mice at 3 hours after birth (Figure 5.3B). Immunohistochemical analysis of 
COX-2 protein expression indicated that the DA of full-term neonatal mice showed 
significantly greater number of COX-2-positive cells than the DA of preterm neonatal 
mice (Figures 5.4C and 5.4D). Furthermore, the COX-2 expression was primarily 
localized in the smooth muscle cells of the DA (Figure 5.4E). Thus, these data establish a 
direct correlation between the attenuated COX-2 expression and increased patent DA.  
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Figure 5.3 Attenuated COX-2 mRNA expression in the DA of preterm neonatal 
mice.  
Preterm (gestation day 17) and full-term (gestation day 19.5) mice were delivered 
by Cesarean section or natural delivery, and sacrificed at 3 hours after birth for analysis 
of COX-1 and COX-2 expression. A) COX-2 mRNA expression is significantly greater 
in the DA of day 19.5 neonates as compared to the DA of day 17 neonates. *, P < 0.05 
(Student's t test), n & 5. B) COX-1 mRNA expression is not significantly different 
between the DA of preterm and full-term neonatal mice. Data are represented as mean 
COX-1 or COX-2 mRNA levels +/- SEM.  
 
A       B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5B
3hr day 17 3hr day 19.5
0.0
0.1
0.2
0.3
Gestational Age
 
 63 
Figures 5.4 Attenuated smooth muscle COX-2 protein expression in the DA of 
preterm neonatal mice. 
C) The DA of a day 17 neonatal mouse at 3 hours after birth shows fewer COX-2-
positive cells as compared to D) the DA of a day 19.5 neonatal mouse at 3 hours after 
birth. Significant lumen is visible in C), indicative of partial DA closure due to 
prematurity. E) DA of a day 19.5 neonatal mouse at 3 hours after birth, stained for 
smooth muscle "-actin. Brown staining (DAB reagent) indicates COX-2 or actin 
expression and sections are counterstained with hematoxylin (blue). Figures shown 
(magnification, X300) are representative of immunohistochemical analysis of neonatal 
DA from a minimum of 5 mice.  
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Discussion 
In humans, patent DA is more common in premature infants, than those born at 
full-term, although mechanisms responsible for the increased incidence are poorly 
understood. We have previously reported that genetic or pharmacological inactivation of 
COX-2 results in patent DA in mice, indicating the importance of COX-2 in postnatal 
closure of the DA.
79, 86
 The current studies were aimed at better understanding the COX-
2-dependent mechanisms of DA closure and elucidating the factors responsible for patent 
DA at preterm gestation. Our findings are the first to suggest that reduced expression of 
COX-2 in the DA at preterm gestation contributes to increased patent DA. 
Our studies are the first to utilize the mouse as a model to examine patent DA at 
preterm gestation. Normal DA closure in mice at full-term gestation is complete within 3 
hours after birth. With our finding that incomplete development resulted in attenuated 
fetal DA constriction, we investigated whether prematurity in gestation also 
compromised normal DA closure after birth. We observed that at 3 hours after birth, DA 
closure was incomplete in preterm neonates, in contrast to the completely remodeled DA 
of 3 hour-old neonates born at full-term gestation. This suggests that similar to humans, 
premature birth compromises postnatal DA closure in mice. 
We have shown that COX-2 expression is induced in the DA of neonatal mice 
following full-term birth, and correlates with the time at which the DA is completely 
remodeled. This suggests that the increased expression of COX-2 is required for the 
normal closure of the vessel after birth. Therefore, we hypothesized that the incomplete 
closure of the DA in preterm gestation neonatal mice that we observed, may result from 
attenuated expression of COX-2. In support of this hypothesis, we found that COX-2 
expression was significantly lower in the DAs of neonatal mice delivered at preterm 
gestation, as compared to that expressed in the DAs of full-term neonates. The reduced 
COX-2 expression corresponded with the time-point at which we observed incomplete 
closure of the preterm neonatal DA. Thus, our studies demonstrate a direct correlation 
between the attenuated expression of COX-2 and the failure of complete closure of the 
DA at preterm gestation.  
Previous studies examining developmental regulation of the COX isoforms in the 
DA have focused on the action of these enzymes in DA dilation. In other species, it has 
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been reported that COX-1 is the predominant isoform expressed in the premature fetal 
DA, whereas COX-2 is primarily expressed in the DA late in gestation.
80
 Our current 
findings in mice are in agreement with previous reports, and show that COX-1 is 
constitutively expressed in the DA throughout gestation, and COX-2 is induced in the DA 
from preterm to full-term gestation. It has also been suggested that the DA at preterm 
gestation is more sensitive to dilation in response to PGE2 derived from the activity of 
COX-1, a process which may contribute to increased postnatal patent DA.
80, 129
 Our work 
emphasizes the importance of COX-2 in mediating DA closure. Because of its potent 
dilatory effect, it is unlikely that PGE2 is the COX-2-derived prostanoid that induces DA 
closure. We propose that COX-2 expressed in the DA synthesizes a prostanoid other that 
PGE2, that directly mediates DA closure. Therefore, patent DA at preterm gestation may 
result from constitutive expression of COX-1 together with the attenuated expression of 
COX-2.  
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Figure 5.5. Proposed model of normal DA closure at full-term gestation and DA 
patency at preterm gestation.  
 At full-term gestation, COX-2 expression is induced, resulting in the 
synthesis of constrictor prostanoid(s); whereas the expression of COX-1 is constitutive in 
the DA, resulting in the synthesis of the dilatory PGE2. At this time-point, the effect of 
the vasoconstrictor overrides the vasodilator, the resultant effect being DA closure. 
However, at preterm gestation, the COX-2 is not induced, whereas the expression of 
COX-1 is constitutive, resulting in the predominant effect of the dilatory PGE2, resulting 
in patent DA.  
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CHAPTER 6 
PROSTANOID RECEPTORS IN THE MOUSE DA 
 
Introduction 
Individual prostanoids act through specific membrane bound receptors to mediate 
their biological responses.
97, 98
 To date, eight types of prostanoid receptors have been 
identified and are highly conserved between mice and humans. Prostanoid receptors are 
G protein-coupled rhodopsin-type receptors with distinct intracellular signaling 
pathways. Mice deficient in each of these receptors have been developed and studies 
using these mice have revealed novel physiological and pathophysiological functions of 
prostanoids.
96, 98
 
In numerous species including humans, PGE2 has long been known to be a potent 
dilator of the DA. There are four known genes that encode the PGE2 receptors, namely 
EP1, EP2, EP3 and EP4. Pharmacological studies have suggested that EP1 and EP3 are 
the contractile receptors, whereas EP2 and EP4 are the dilatory receptors.
104, 105, 110
 
Because of the known vasodilatory function of PGE2 on the DA, there has been 
considerable interest in identifying the major PGE2 receptor expressed in the DA to better 
understand the role of PGE2 in mediating ductal dilation. 
There have been several studies in a variety of animal species including lamb, 
baboon, rat, rabbit and pig, examining the expression of the EP receptors in the DA. Of 
all the EP receptors, EP4 is the one that is thought to be primarily expressed in the DA. 
However, there have been conflicting results regarding expression of the other EP 
receptors, as well the expression pattern of all the EP receptors in the DA during the 
transition from fetal to neonatal life. Studies using the rabbit DA suggest that only the 
EP4 receptor is present in the DA, whereas in the porcine DA, EP2, EP3 and EP4 are 
expressed in equivalent proportions. These studies using the porcine DA also suggest that 
expression of EP3 and EP4 is down-regulated in the newborn. Another study by Smith et 
al., utilized pharmacological agents to examine ligand-receptor binding, and suggested 
that expression of the EP4 receptor declined with advancing gestational age, whereas 
more recent studies using similar techniques have suggested that the expression of this 
receptor does not change.
102
 Thus overall, depending on the species, gene expression in 
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the DA for EP2, EP3 and EP4 does not change, decreases, or increases with advancing 
gestation.
99, 102, 103, 105, 107, 110
 
Most reports to date have focused on examining expression of prostanoid 
receptors responsible for maintaining DA dilation. Our recent studies using mice 
deficient in the COX isoforms indicated the importance of COX-2 expression for DA 
closure after birth. We also demonstrated that the DA expresses high levels of COX-2 
during normal closure after birth, suggesting novel contractile actions of COX-2-
dependent prostanoids in the DA. These studies suggested that a prostanoid in addition to 
the dilatory PGE2 was synthesized in the DA, which mediated DA closure. The report by 
Smith et al., for the first to suggest contractile actions of agonists for the TXA2 receptor 
TP, as well those for the PGE2 receptors EP1 and EP3.
107
 The studies were performed 
using pharmacological techniques to measure ex vivo contractile effects of prostanoid or 
prostanoid agonists. In our recent study, we utilized a variety of prostanoid analogs to 
examine the in vivo effects of these agents in mediating DA contraction. Of all the 
pharmacological agents that we examined, only the PGH2 analog U46619, and the TXA2 
analog, IBOP that are known to bind the TXA2 receptor TP, mediated DA contraction in 
vivo.
86
 Previous studies have suggested that the DA does not express TXA2 synthase, and 
therefore does not synthesize TXA2.
107
 Based on these studies together with our previous 
studies, it is possible that PGH2 may be the prostanoid that actively mediates normal DA 
closure. Furthermore, these studies implicated a role for the TP receptor in DA closure. 
The studies by Smith et al., showed that the TP receptor is expressed in the rabbit DA.
107
 
In the current studies, we utilized mouse DA to examine the expression of the various 
prostanoid receptors in the DA.  
In addition to the COX-deficient mice, mice deficient in the EP4 receptor also 
exhibit a patent DA phenotype,
100, 101
 which is a surprising finding based on the known 
dilatory role for PGE2. Based on our studies, we believe that an induction in COX-2 
expression is important for closure of the DA after birth in mice. However, the 
mechanisms responsible for the induction in COX-2 expression are not clear. Because of 
the known role of COX-2 in DA closure, we hypothesized that the failure of DA closure 
in the EP4-deficient mice may be due to attenuated expression of COX-2.  
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Results 
Quantitation of prostanoid receptors in the fetal DA at multiple stages of gestation.  
Previous reports have suggested that the prostanoid receptors EP2, EP3, EP4 and 
TP may be involved in modulating DA tone. In the current studies, we examined mRNA 
expression levels for these prostanoid receptors. As shown in Figure 6.1A, the fetal 
mouse DA expressed a significant level of TP, however, the level of expression did not 
significantly change throughout gestation. EP2 mRNA expression was nearly 
undetectable in the fetal DA (data not shown). The expression of EP3 mRNA was 
constitutive in the fetal DA, when examined on days 16, 17 and 19.5 of gestation (Figure 
6.1B). In contrast, expression of the EP4 receptor in the fetal mouse DA increased 
significantly from gestation days 16 to 19.5 (Figure 6.1C). 
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Figure 6.1 
Expression of EP4, but not EP3 or TP, increases with advancing gestational age.  
Preterm (gestation days 16 and 17) and full-term (gestation day 19.5) mice were 
obtained at 0 hours (sacrificed immediately after birth) for analysis of mRNA expression 
in the DA. Data represented as mean A) TP, B) EP3 and C) EP4 mRNA levels +/- SEM. 
EP4 mRNA expression in the DA significantly increased throughout gestation, P < 0.05 
(one-way ANOVA), n & 8. 
 
A 
 
 
C 
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Reduced COX-2 mRNA expression in the DA of EP4-deficient neonatal mice.  
In addition to the COX-deficient mice, mice deficient in the PGE2 receptor EP4 
also exhibit a patent DA phenotype.
100, 101
 This finding is surprising because it is well 
established that PGE2 produces dilation of the DA.
2
 Furthermore, there is no evidence 
that EP4 receptor activation is involved in constriction of the smooth muscle of the DA or 
any other vasculature. Having determined that the pattern of expression of EP4 receptor 
mRNA mimics that of COX-2 expression, we hypothesized that the expression of EP4 
may be required for the induction of COX-2 in the mouse DA. We therefore examined 
COX-2 expression in the DAs of EP4-deficient neonatal mice with a patent DA, as 
compared to EP4 expressing neonatal mice with a closed DA. Our results indicate that 
COX-2 expression was significantly attenuated in the DAs of EP4-deficient mice at 3 
hours after birth, as compared to that in the DAs of littermate EP4 heterozygous or wild-
type mice (Figure 6.2). These data suggest that an interplay between EP4 and COX-2 
may be required for the initiation of DA closure after birth.  
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Figure 6.2  
Reduced COX-2 expression in the DA of EP4-deficient neonatal mice.  
Full-term gestation (day 19.5) EP4 wild-type (EP4
+/+
), heterozygous (EP4
+/–
) and 
homozygous-deficient (EP4
–/–
) mice were obtained by natural delivery and sacrificed 3 
hours after birth for analysis of COX-2 expression in the DA. Data represented as mean 
COX-2 mRNA levels +/- SEM. *, significantly different from EP4
+/+
 and EP4
+/–
 DA, P < 
0.01 (one-way ANOVA), n & 8.  
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Discussion 
PGE2 mediates its biological functions by binding to 4 different receptors, namely 
EP1, EP2, EP3 and EP4. PGE2 mediates different biological responses depending on the 
expression of a specific receptor in a particular tissue. Traditionally, based mainly on 
pharmacological experiments, both EP2 and EP4 are thought to maintain relaxation 
responses through a cyclic AMP-dependent mechanism, whereas EP1 and EP3 are 
thought to be the contractile receptors.
97
 A recent study identified an additional 
contractile function of EP3 in the DA.
104
 Because PGE2 is a known potent dilator of the 
DA, several studies in numerous species have focused on examining EP receptor 
expression in the DA to better understand the role of PGE2 in modulating DA tone. 
Depending on the species, gene expression in the DA for EP2, EP3 and EP4 does not 
change, decreases, or increases with advancing gestation.
102, 103, 105
 Of the known PGE2 
receptors, EP4 expression in the DA is most conserved between species such as rabbits, 
mice, lambs, baboon and humans. Therefore, it has been thought that EP4 is the primary 
receptor through which PGE2 mediates its dilatory actions on the DA. 
Because of its known dilatory function on the DA, studies to date have focused on 
the targeting the EP4 receptor for the regulation of DA tone. A recent study utilized a 
pharmacological antagonist specific for the EP4 receptor, for causing constriction of the 
DA in rats.
130
 The EP4 receptor antagonist ONO-AE3 208 was administered to fetal rats 
in utero, or to neonatal rats pre-treated with a PGE2 analogue or vehicle. The EP4 
antagonist caused premature closure of the fetal DA, as well as induced closure of the DA 
in neonatal rats pre-treated with PGE2. From this study, the authors concluded the EP4 
was the primary dilatory receptor present in the rat DA, and targeting this receptor might 
be an alternate treatment for patent DA. 
Another study from the same group also examined the effect of EP4 activation for 
causing DA dilation in neonatal rats after birth.
131
 Similar to mice, DA closure in rats is 
complete within a few hours, whereas it takes a few days in human beings. There are 
certain congenital heart malformations in humans, such as coarctation of the aorta, that 
require keeping the DA patent after birth. Because of the potent dilatory function of PGE2 
on the DA, administration of a PGE2 analogue is most often used as treatment for such 
conditions, however it is associated with certain side effects. The rationale of this study 
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by Momma et al., was that targeting the EP4 receptor specifically might be better than a 
PGE2 analog, for treatment of defects such as coarctation of the aorta. In the study by 
Momma et al., the EP4 agonist was compared to the PGE2 analog, as well as to another 
agonist specific for EP2, and the potential dilatory effects of the drugs were examined on 
already closed DAs of neonatal rats.
131
 These studies showed that the EP4 agonist 
effectively caused DA dilation, and to a greater extent than that caused by the PGE2 
analog. Similar to their previous studies, the authors concluded that the EP4 receptor is 
the primary receptor responsible for mediating DA dilation. Furthermore, activation of 
the EP4 receptor might be a better treatment for congenital heart defects, where the DA is 
required to be open. 
Most studies to date have focused on the dilatory function of the EP4 receptor. 
Our current study proposes an alternate role for the EP4 receptor in the DA. Of the EP 
receptors that we examined in our current studies, only EP4 mRNA expression 
significantly increased with advancing gestation. Our studies also show that COX-2 
expression in the DA significantly increased with advancing gestation, and the induction 
in COX-2 expression is essential for mediating DA closure. Thus, the gestational 
expression pattern of EP4 mimicked that which we observed for COX-2. The co-
regulation of EP4 and COX-2 suggests a relationship between this prostanoid receptor 
and COX-2, for inducing DA closure. Our studies propose, that in addition to the dilatory 
role, activation of the EP4 receptor functions as a trigger for the induction of COX-2 
expression important for DA closure. However, the mechanism(s) responsible for 
mediating the induction of COX-2 in the DA are not clear. In other cell types, EP4 
activation is known to induce COX-2 expression.
132, 133
 Our studies indicate that the 
genetic deficiency of EP4 results in attenuated COX-2 expression in the DA. Thus, our 
results provide an explanation for the paradoxical finding of patent DA in the EP4-
deficient mice, and suggest that EP4 expression may be important for modulating the 
normal induction of COX-2 and resultant DA closure after full-term birth. We propose 
that EP4 receptor activation at full-term gestation initiates a signaling cascade modulating 
the up-regulation of COX-2 expression and resultant DA closure.  
The primary signaling pathway following EP4 activation that has been identified 
involves an increase in intracellular cAMP, and increased cAMP levels are known to 
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induce COX-2 expression.
31, 42, 97, 134
 The increase in cAMP activates protein kinase A 
(PKA) which phosphorylates the cAMP response element binding protein (CREB). 
CREB is a transcription factor known to induce COX-2 expression by binding to the 
cAMP response element (CRE) regulatory site present in the COX-2 promoter.
31, 42, 52
 
However, increased cAMP is associated with dilation of the DA.
104
 Because we know 
that increased COX-2 expression is important for DA closure, and because of the 
potential opposing dilatory action of cAMP, it is not likely that the cAMP-PKA pathway 
is the primary mechanism utilized by EP4 for induction of COX-2 in the DA. In addition 
to the traditional cAMP-dependent pathway, recently it has been shown that EP4 receptor 
activation initiates other signaling pathways which may be cAMP-independent.
132, 135-137
 
EP4 receptor stimulation activates phosphatidylinositol (PI) 3-kinase, resulting in 
activation of the transcription factor, T-cell factor 4 (Tcf-4).
136
 Transcriptional activation 
of Tcf-4 has been shown to up-regulate the expression of COX-2 by binding to a Tcf 
binding element (TBE) recently discovered in the COX-2 promoter.
138
 Therefore, it has 
been proposed that EP4 activation may be another mechanism by which COX-2 
expression is induced in pathological conditions (Figure 6.3).
132, 135
 Until our studies, the 
interplay between EP4 and COX-2-induced DA closure has not been investigated. The 
idea that PGE2 may induce the expression of COX-2 has been shown previously in 
various cell culture systems.
139, 140
 However, the EP4-deficient mice provide a unique in 
vivo model to study endogenous prostanoid signaling mechanisms resulting in the 
dramatic upregulation of COX-2 that we observe. Overall, these studies explain the 
mechanism by which an individual prostanoid, PGE2, may have opposing effects on DA 
physiology. One of the opposing effects is dilation, which is a well-characterized function 
of PGE2 in the DA; whereas in our studies we suggest an indirect effect of PGE2 leading 
to the induction of COX-2 and the resulting synthesis of constrictor prostanoid, possibly 
PGH2.  
A recent study examined the gestational expression pattern of the prostanoid 
receptors in the fetal rat DA. They showed that EP2, EP3 and EP4 were expressed in the 
fetal DA throughout gestation. However, the expression of EP4 was the greatest towards 
the end of term.
106
 These findings are in accordance with are current results showing that 
EP4 expression in the fetal DA increases with advancing gestation. Furthermore, these 
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studies by Yokoyama et al., also propose an additional active role for the EP4 receptor in 
mediating DA closure.
106
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Figure 6.3. Proposed model for the induction of COX-2 expression following EP4 
activation.  
Stimulation of the EP4 receptor by PGE2 activates phosphatidylinositol (PI) 3-
kinase, resulting in phosphorylation of AKT. This results in translocation of !-catenin 
(!cat) to the nucleus and activation of the transcription factor, T-cell factor 4 (Tcf 4). 
Transcriptional activation of Tcf 4 has been shown to up-regulate the expression of COX-
2 by binding to a Tcf binding element (TBE) recently discovered in the COX-2 
promoter.
132, 133, 136
 Therefore, we propose that EP4 activation may be another mechanism 
by which COX-2 expression is induced in the DA.  
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CHAPTER 7 
GENERAL DISCUSSION 
 
Summary and Conclusions  
Previous studies from our laboratory, in mice with the genetic or pharmacological 
inactivation of COX-2 have emphasized a role for this enzyme in the postnatal closure of 
the DA. The goal of the current studies was to determine the mechanisms responsible for 
increased patent DA at preterm gestation.  
First, the effect of gestational age on indomethacin-induced constriction of the 
fetal DA or wild-type mice was determined. It was demonstrated that administration of 
indomethacin to pregnant female mice on gestation day 18.5 resulted in premature 
constriction of the DA in utero. However, indomethacin induced only a partial 
constriction of the fetal mouse DA, when administered on gestation day 16. These 
findings were in accordance with several previous studies in other species. Therefore it 
was concluded that the contractile function of the DA developed late in gestation. These 
studies also showed that the expression of COX-2 significantly increased with advancing 
gestational age, whereas the expression of COX-1 remained constitutive. The time-points 
at which observed the lowest and greatest level of COX-2 expression in the fetal DA 
were observed, coincided with the time-points at which attenuated and increased in utero 
DA constriction were observed respectively. Therefore it was concluded that the 
expression of COX-2 was important for the in utero development of ductal contractile 
function. 
 
I then wanted to investigate the effect of gestational age on postnatal DA closure 
in wild-type mice. These studies showed that similar to humans, DA closure was 
compromised in neonatal mice born at preterm gestation. It was also found that COX-2 
expression was attenuated in the DA of neonatal mice born at preterm gestation, whereas 
the expression of COX-1 did not significantly change. These studies suggested that 
attenuated COX-2 expression might contribute to increased patent DA at preterm 
gestation. Thus, these studies also provide a novel animal model for studying the 
mechanisms of patent DA.  
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I also utilized another model of patent DA in mice resulting from the deficiency 
of the PGE2 receptor EP4. PGE2 has long been known to be a potent dilator of the DA; 
therefore the finding of a patent DA in EP4-deficient mice was surprising. Because of the 
current studies emphasizing a role for COX-2 in DA closure, it was hypothesized that a 
failure of induction in COX-2 expression resulting in patent DA in the EP4-deficient 
mice. In support of this hypothesis, it was found that COX-2 expression was significantly 
attenuated in neonatal mice deficient in the EP4 receptor. These studies suggested a role 
for EP4 in the induction of COX-2 in the DA. It was also found that in the fetal DA the 
expression of EP4 followed a pattern similar to that of COX-2, during advancing 
gestation. Thus, these studies provided evidence for an additional role for EP4 in the 
developmental regulation of DA contractile function.  
These studies have provided a better insight into the mechanisms responsible for 
patent DA and for the development of novel therapeutics for this serious congenital heart 
defect.  
 
Clinical Relevance and Future Directions 
Previous studies have demonstrated that in other species COX-1 is constitutively 
expressed in the DA of both full-term and preterm neonates
80, 123
. The current studies also 
show that COX-1 is constitutively expressed in the DA of fetal and neonatal mice at all 
stages of gestation and after birth. Even though COX-2 has been suggested to be 
responsible for synthesizing the majority of PGE2 in the fetal DA at the end of gestation, 
COX-1 is thought to be the major contributor of PGE2 synthesis in the DA of the 
premature fetus.
80, 141
 It has also been suggested that the preterm gestation fetal DA is 
more sensitive to the dilatory effects of PGE2 
105, 142, 143
, which may contribute to the 
increased patent DA at preterm. We believe that in preterm neonates with reduced 
expression of COX-2 in the DA, the dilatory effect of COX-1-derived PGE2 
predominates over COX-2-dependent DA constriction, thus resulting in the failure of DA 
closure. This hypothesis suggests that inhibition of COX-1-derived PGE2 in preterm 
neonates will increase postnatal DA closure. Therefore, future studies in the Loftin 
laboratory will examine the effect of postnatal administration of a COX-1-specific 
inhibitor on accelerating DA closure in preterm neonatal mice. Recently, a COX-1-
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specific inhibitor (SC-560) has been developed and surprisingly, it lacks the gastric 
toxicity of classical COX inhibitors such as indomethacin, which inhibit both COX-1 and 
COX-2.
144-146
 We have also recently shown that this COX-1 inhibitor does not adversely 
affect fetal or neonatal health like nonselective or COX-2-selective inhibitors.
86
 
Therefore, COX-1-specific inhibition may be more safe and effective than the current 
pharmacological or surgical treatments for patent DA in preterm infants (Figure 7).  
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Figure 7. COX-1 inhibitor treatment for patent DA at preterm gestation. 
At preterm gestation, the effect of COX-1-derived PGE2 predominates over the 
vasoconstrictor synthesized by the reduced COX-2, resulting in DA patency. At this time-
point, administration of a COX-1 inhibitor may accelerate DA closure by inhibiting the 
PGE2 and resulting in the vasoconstrictor overriding the vasodilator.  
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In utero gene therapy has long been proposed as a valuable therapeutic approach 
for treating congenital cardiovascular disease.
6, 147
 There are certain congenital heart 
defects that involve a malformed aorta, that require re-directing blood circulation to the 
descending aorta, through a patent DA. In such conditions PGE2 analogs are the first line 
treatment, followed by surgery. A recent study by Humpl et al. demonstrated a unique 
gene therapy approach which resulted in the efficacious transfer of the PGE2 synthase 
gene, to maintain patency of the DA and the production of PGE2.
148
 This novel method 
involved encapsulation of DNA in lipid membranes fused with UV-inactivated 
hemagglutinating virus for efficient transfection using a custom-made catheter based 
system.
148
 This study was the first to report successful gene transfer for maintaining DA 
patency in an animal model. Future studies in our lab will involve utilization of a similar 
technique for transfer of the COX-2 gene in the DA of preterm neonates in order to 
identify a novel treatment for patent DA. The main drawback of this gene therapy method 
is similar to that observed with adenovirus mediated gene transfer, which is the transient 
expression of the transgene.
149, 150
 However, the DA has a unique vascular physiology 
which involves rapid constriction and tissue remodeling, followed by matrix deposition 
and apoptosis that results in the formation of nonfunctional remnant scar tissue known as 
the ligamentum arteriosum.
151
 Once the ligamentum arteriosum is formed in the early 
postnatal period, COX-2 expression is no longer expected to be required. Therefore, in 
our system, transient expression of the COX-2 transgene will be advantageous, and is 
expected to be sufficient to correct this congenital cardiovascular defect, as it may mimic 
the endogenous pattern of perinatal COX-2 expression in the DA.  
Future studies in the Loftin laboratory will also utilize another method of gene 
therapy using the established adenovirus-mediated method. We have identified the 
intermediate filament protein, desmin, as a marker indicative of the advanced 
development of contractile machinery in DA smooth muscle. In addition to the DA, 
desmin is also known to be expressed in skeletal and cardiac muscle, as well as venous 
smooth muscle.
152-155
 However, it has recently been reported in mice that a distal 5' 
fragment together with a cis element enhancer of the desmin promotor can be utilized to 
direct reporter gene expression specifically to arterial SMCs in vivo, and prevent 
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expression in other types of muscle.
156
 Our studies in mice show a dramatically greater 
level of desmin expression in DA SMCs as compared to SMCs of the aorta and adjacent 
arteries. Therefore, in our future studies, we will utilize the specific regulatory regions of 
the desmin promotor to direct adenovirus-mediated COX-2 expression to DA smooth 
muscle.  
The COX-1/COX-2 double homozygous-deficient knockout mice, which show a 
100% incidence of postnatal patent DA
79
, as well as preterm COX-2 wild-type mice 
which show attenuated DA closure, are two mouse models of patent DA that we have 
already established. We will use these two unique models to determine the effectiveness 
of adenoviral COX-2 gene delivery to facilitate DA closure. Overall, these studies will 
provide insight into the development of potential gene therapy approaches for treating 
patent DA in premature infants, and thereby eliminate the requirement for surgical 
intervention. Preterm birth is the leading cause of neonatal morbidity and mortality 
worldwide, and the outcome of preterm infants is directly related to the gestational age at 
delivery. There are several agents including magnesium sulfate, oxytocin receptor 
antagonists, calcium channel blockers, and NSAIDs that are used to delay the onset of 
premature labor.
157-160
 These drugs have been shown to be effective in delaying labor in 
the short term from 24 to 48 hours, and in some rare cases up to 7 days; however, their 
efficacy for the long-term tocolytic maintenance necessary to significantly improve 
neonatal health has not been demonstrated. The goal of tocolytic therapy is to delay labor 
sufficiently to allow for the administration of corticosteroids to the neonate, thereby 
improving lung compliance and reducing the risk for respiratory distress. During this 
time of prolonged labor in the short term, administration of a pharmacological agent that 
triggers an induction in COX-2 expression in the DA would be advantageous. Increasing 
COX-2 expression in the DA at that time may promote development of the vessel and 
allow for normal closure after preterm birth, thereby reducing morbidity and mortality. 
Based on our current studies, we believe that the EP4 receptor performs a unique and 
previously un-identified function in the DA that involves the induction of COX-2 
expression that is important for the development of the contractile machinery in the 
vessel. Therefore, it is feasible to propose that treatment with an EP4-selective agonist 
during pregnancy may result in increased COX-2 expression and allow for normal 
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closure of the DA in preterm neonates. Although the idea that PGE2 may induce the 
expression of COX-2 has been shown previously in various cell culture systems, our 
model of DA closure is a unique in vivo model to study endogenous prostanoid signaling 
mechanisms resulting in the dramatic upregulation of COX-2 that we observe.  
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